|
US8505468B2
(en)
*
|
2002-11-19 |
2013-08-13 |
Sharp Kabushiki Kaisha |
Substrate accommodating tray
|
|
US9745103B2
(en)
|
2006-05-05 |
2017-08-29 |
Illinois Tool Works Inc. |
Wide mouth gusseted pouches
|
|
EP2471816A1
(en)
|
2006-08-30 |
2012-07-04 |
Genentech, Inc. |
Multispecific antibodies
|
|
HRP20160082T1
(hr)
|
2006-09-29 |
2016-02-26 |
Oncomed Pharmaceuticals, Inc. |
Sastavi i postupci za dijagnosticiranje i lijeäśenje raka
|
|
CN101952312A
(zh)
*
|
2007-07-31 |
2011-01-19 |
米迪缪尼有限公司 |
多特异性表位结合蛋白及其应用
|
|
ES2687808T3
(es)
|
2007-09-26 |
2018-10-29 |
Chugai Seiyaku Kabushiki Kaisha |
Región constante de anticuerpo modificado
|
|
US20090162359A1
(en)
|
2007-12-21 |
2009-06-25 |
Christian Klein |
Bivalent, bispecific antibodies
|
|
SG188802A1
(en)
*
|
2008-03-06 |
2013-04-30 |
Genentech Inc |
Combination therapy with c-met and egfr antagonists
|
|
NZ601815A
(en)
*
|
2008-03-31 |
2014-10-31 |
Genentech Inc |
Compositions and methods for treating and diagnosing asthma
|
|
US8790642B2
(en)
|
2008-08-29 |
2014-07-29 |
Genentech, Inc. |
Cross-reactive and bispecific anti-IL-17A/F antibodies
|
|
AR073538A1
(es)
*
|
2008-09-03 |
2010-11-17 |
Genentech Inc |
Anticuerpos multiespecificos que se unen especificamente al receptor del factor de crecimiento epidermico humano 2 (her2) y al factor de crecimiento endotelial vascular (vegf)
|
|
TWI544077B
(zh)
|
2009-03-19 |
2016-08-01 |
中外製藥股份有限公司 |
Antibody constant region change body
|
|
KR20150036824A
(ko)
|
2009-03-20 |
2015-04-07 |
제넨테크, 인크. |
이중특이적 항-ｈｅｒ 항체
|
|
CN103755808B
(zh)
|
2009-03-25 |
2016-02-10 |
霍夫曼-拉罗奇有限公司 |
抗-α5β1抗体及其应用
|
|
US9067986B2
(en)
|
2009-04-27 |
2015-06-30 |
Oncomed Pharmaceuticals, Inc. |
Method for making heteromultimeric molecules
|
|
US9676845B2
(en)
|
2009-06-16 |
2017-06-13 |
Hoffmann-La Roche, Inc. |
Bispecific antigen binding proteins
|
|
EP3485908B1
(en)
|
2009-10-16 |
2021-08-18 |
Mereo BioPharma 5, Inc. |
Therapeutic combination and use of dll4 antagonist antibodies and anti-hypertensive agents
|
|
EP2513148B1
(en)
|
2009-12-16 |
2016-08-31 |
AbbVie Biotherapeutics Inc. |
Anti-her2 antibodies and their uses
|
|
ES2519348T3
(es)
|
2010-02-18 |
2014-11-06 |
Genentech, Inc. |
Antagonistas de neurregulina y uso de los mismos en el tratamiento del cáncer
|
|
KR101899835B1
(ko)
|
2010-03-24 |
2018-09-19 |
제넨테크, 인크. |
항-ｌｒｐ６ 항체
|
|
US10745467B2
(en)
|
2010-03-26 |
2020-08-18 |
The Trustees Of Dartmouth College |
VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
|
|
CN103119054B
(zh)
|
2010-03-26 |
2017-01-18 |
达特茅斯大学理事会 |
Vista调节性t细胞介体蛋白、vista结合剂及其用途
|
|
US20150231215A1
(en)
|
2012-06-22 |
2015-08-20 |
Randolph J. Noelle |
VISTA Antagonist and Methods of Use
|
|
WO2011147834A1
(en)
|
2010-05-26 |
2011-12-01 |
Roche Glycart Ag |
Antibodies against cd19 and uses thereof
|
|
CN103080136B
(zh)
|
2010-06-18 |
2015-08-12 |
霍夫曼-拉罗奇有限公司 |
抗Axl抗体及使用方法
|
|
WO2011161119A1
(en)
|
2010-06-22 |
2011-12-29 |
F. Hoffmann-La Roche Ag |
Antibodies against insulin-like growth factor i receptor and uses thereof
|
|
WO2011161189A1
(en)
|
2010-06-24 |
2011-12-29 |
F. Hoffmann-La Roche Ag |
Anti-hepsin antibodies and methods of use
|
|
NZ605449A
(en)
|
2010-07-09 |
2015-03-27 |
Genentech Inc |
Anti-neuropilin antibodies and methods of use
|
|
WO2012010549A1
(en)
|
2010-07-19 |
2012-01-26 |
F. Hoffmann-La Roche Ag |
Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
|
|
CN104634971A
(zh)
|
2010-07-19 |
2015-05-20 |
霍夫曼-拉罗奇有限公司 |
鉴定响应抗癌疗法的可能性升高的患者的方法
|
|
WO2012010582A1
(en)
|
2010-07-21 |
2012-01-26 |
Roche Glycart Ag |
Anti-cxcr5 antibodies and methods of use
|
|
KR20130045914A
(ko)
|
2010-08-03 |
2013-05-06 |
에프. 호프만-라 로슈 아게 |
만성 림프구성 백혈병(cll) 생체지표
|
|
BR112013002532A2
(pt)
|
2010-08-05 |
2016-05-31 |
Hoffmann La Roche |
proteína de fusão de citocina anti-viral do anticorpo anti-mhc
|
|
BR112013002444A2
(pt)
|
2010-08-13 |
2016-05-24 |
Roche Glycart Ag |
anticorpo, polinucleotídeo e polipeotídeo isolados, composição, vetor, cécula hospedeira, conjulgado de anticorpo, formulação farmacêutica, uso do anticorpo, métodos para produzir um anticorpo, tratar um indivíduo, induzir a lise celular de uma célula tumorosa e diagnosticar uma doença em um indivíduo
|
|
PE20171512A1
(es)
|
2010-08-13 |
2017-10-20 |
Roche Glycart Ag |
Anticuerpos anti-fap
|
|
CN104474546A
(zh)
|
2010-08-13 |
2015-04-01 |
弗·哈夫曼-拉罗切有限公司 |
用于疾病治疗的针对IL-1β和IL-18的抗体
|
|
KR101603001B1
(ko)
|
2010-08-25 |
2016-03-11 |
에프. 호프만-라 로슈 아게 |
Il-18r1에 대한 항체 및 그의 용도
|
|
SG10201408229WA
(en)
|
2010-08-31 |
2015-02-27 |
Genentech Inc |
Biomarkers and methods of treatment
|
|
TW201302793A
(zh)
|
2010-09-03 |
2013-01-16 |
Glaxo Group Ltd |
新穎之抗原結合蛋白
|
|
US8551479B2
(en)
|
2010-09-10 |
2013-10-08 |
Oncomed Pharmaceuticals, Inc. |
Methods for treating melanoma
|
|
AU2011326564A1
(en)
|
2010-11-10 |
2013-05-09 |
Genentech, Inc. |
Methods and compositions for neural disease immunotherapy
|
|
CN103443125B
(zh)
|
2010-11-30 |
2019-05-03 |
霍夫曼-拉罗奇有限公司 |
低亲和力血脑屏障受体抗体及其用途
|
|
US20120134924A1
(en)
*
|
2010-11-30 |
2012-05-31 |
Magnetus, Llc |
Micro-Vesicles Providing Contrast To Target Tissue Electrical Property Gradients
|
|
KR101615420B1
(ko)
|
2010-12-16 |
2016-04-26 |
제넨테크, 인크. |
Th2 억제에 관한 진단 및 치료
|
|
AU2011349443B2
(en)
|
2010-12-20 |
2015-12-24 |
Genentech, Inc. |
Anti-mesothelin antibodies and immunoconjugates
|
|
CN103261230A
(zh)
|
2010-12-22 |
2013-08-21 |
霍夫曼-拉罗奇有限公司 |
抗pcsk9抗体及使用方法
|
|
JP5768147B2
(ja)
|
2011-02-28 |
2015-08-26 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
一価抗原結合タンパク質
|
|
WO2012116926A1
(en)
|
2011-02-28 |
2012-09-07 |
F. Hoffmann-La Roche Ag |
Antigen binding proteins
|
|
LT2691417T
(lt)
|
2011-03-29 |
2018-10-25 |
Roche Glycart Ag |
Antikūno fc variantai
|
|
CA2828890A1
(en)
|
2011-04-07 |
2012-10-11 |
Genentech, Inc. |
Anti-fgfr4 antibodies and methods of use
|
|
RU2013150331A
(ru)
|
2011-04-20 |
2015-05-27 |
Рош Гликарт Аг |
СПОСОБ И УСТРОЙСТВА ДЛЯ рН-ЗАВИСИМОГО ПРОХОЖДЕНИЯ ГЕМАТОЭНЦЕФАЛИЧЕСКОГО БАРЬЕРА
|
|
EP2707723B1
(en)
|
2011-05-12 |
2016-02-10 |
Genentech, Inc. |
Multiple reaction monitoring lc-ms/ms method to detect therapeutic antibodies in animal samples using framework signature pepides
|
|
WO2012158704A1
(en)
|
2011-05-16 |
2012-11-22 |
Genentech, Inc. |
Fgfr1 agonists and methods of use
|
|
SG195196A1
(en)
*
|
2011-05-27 |
2013-12-30 |
Dutalys |
Dual targeting
|
|
US20140255405A1
(en)
|
2011-05-27 |
2014-09-11 |
Dutalys |
Removal of Monomeric Targets
|
|
WO2012171996A1
(en)
|
2011-06-15 |
2012-12-20 |
F. Hoffmann-La Roche Ag |
Anti-human epo receptor antibodies and methods of use
|
|
RU2013155695A
(ru)
|
2011-06-30 |
2015-08-10 |
Дженентек, Инк. |
Препараты антител против с-мет
|
|
BR112014003431A2
(pt)
|
2011-08-17 |
2017-06-13 |
Genentech Inc |
anticorpo, ácido nucleico, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, agente farmacêutico, uso do anticorpo, método de tratamento de um indivíduo que tem câncer e método de aumento de tempo para recorrência de tumor
|
|
JP2014534806A
(ja)
|
2011-08-23 |
2014-12-25 |
ロシュ グリクアート アーゲー |
抗ｍｃｓｐ抗体
|
|
SG2014011316A
(en)
|
2011-08-31 |
2014-06-27 |
Genentech Inc |
Diagnostic markers
|
|
CN103930781A
(zh)
|
2011-09-15 |
2014-07-16 |
霍夫曼-拉罗奇有限公司 |
促进分化的方法
|
|
AU2012312515A1
(en)
|
2011-09-19 |
2014-03-13 |
Genentech, Inc. |
Combination treatments comprising c-met antagonists and B-raf antagonists
|
|
TWI583699B
(zh)
|
2011-09-23 |
2017-05-21 |
安可美德藥物股份有限公司 |
Ｖｅｇｆ／ｄｌｌ４結合劑類及彼等之用途
|
|
JP2014531213A
(ja)
|
2011-09-30 |
2014-11-27 |
ジェネンテック， インコーポレイテッド |
上皮又は間葉の表現型の診断用メチル化マーカー、及び腫瘍又は腫瘍細胞におけるｅｇｆｒキナーゼ阻害薬に対する応答
|
|
US20130089562A1
(en)
|
2011-10-05 |
2013-04-11 |
Genenthech, Inc. |
Methods of treating liver conditions using notch2 antagonists
|
|
PE20141562A1
(es)
|
2011-10-14 |
2014-11-12 |
Genentech Inc |
Anticuerpos anti-htra1 y metodos de uso
|
|
US9358250B2
(en)
|
2011-10-15 |
2016-06-07 |
Genentech, Inc. |
Methods of using SCD1 antagonists
|
|
WO2013059531A1
(en)
|
2011-10-20 |
2013-04-25 |
Genentech, Inc. |
Anti-gcgr antibodies and uses thereof
|
|
WO2013059740A1
(en)
|
2011-10-21 |
2013-04-25 |
Foundation Medicine, Inc. |
Novel alk and ntrk1 fusion molecules and uses thereof
|
|
KR20140097205A
(ko)
|
2011-10-28 |
2014-08-06 |
제넨테크, 인크. |
흑색종을 치료하는 치료 조합물 및 방법
|
|
SG11201402485UA
(en)
|
2011-11-21 |
2014-06-27 |
Genentech Inc |
Purification of anti-c-met antibodies
|
|
EP2788024A1
(en)
|
2011-12-06 |
2014-10-15 |
F.Hoffmann-La Roche Ag |
Antibody formulation
|
|
EP2602265A1
(en)
*
|
2011-12-07 |
2013-06-12 |
Centre National de la Recherche Scientifique (CNRS) |
Antibodies anti-sPLA2-X and uses thereof
|
|
SG10201700169PA
(en)
|
2011-12-22 |
2017-02-27 |
Hoffmann La Roche |
Expression vector element combinations, novel production cell generation methods and their use for the recombinant production of polypeptides
|
|
CN107881196A
(zh)
|
2011-12-22 |
2018-04-06 |
弗·哈夫曼-拉罗切有限公司 |
表达载体组织、新的生产用细胞产生方法及其在重组产生多肽中的用途
|
|
AR089434A1
(es)
|
2011-12-23 |
2014-08-20 |
Genentech Inc |
Procedimiento para preparar formulaciones con alta concentracion de proteinas
|
|
SG10201601747XA
(en)
|
2012-01-18 |
2016-04-28 |
Genentech Inc |
Anti-LRP5 Antibodies And Methods Of Use
|
|
RU2014133547A
(ru)
|
2012-01-18 |
2016-03-10 |
Дженентек, Инк. |
Способы применения модуляторов fgf19
|
|
BR112014019741A2
(pt)
|
2012-02-11 |
2020-12-22 |
Genentech, Inc |
Usos de um antagonista da via wnt, uso de uma terapia anticâncer, método de identificação de um indivíduo com câncer, métodos para prever, método de inibição da proliferação de uma célula de câncer, uso de um antagonista da translocação de r-spondina e antagonista da translocação de r-spondina isolado
|
|
KR102069397B1
(ko)
|
2012-02-15 |
2020-01-22 |
에프. 호프만-라 로슈 아게 |
Ｆｃ-수용체 기재 친화성 크로마토그래피
|
|
CN102633883B
(zh)
*
|
2012-02-24 |
2014-06-25 |
上海白泽生物科技有限公司 |
一种能与egfr、her2、vegf高效结合的融合蛋白、其编码序列及用途
|
|
WO2013148315A1
(en)
|
2012-03-27 |
2013-10-03 |
Genentech, Inc. |
Diagnosis and treatments relating to her3 inhibitors
|
|
AR090549A1
(es)
|
2012-03-30 |
2014-11-19 |
Genentech Inc |
Anticuerpos anti-lgr5 e inmunoconjugados
|
|
WO2013157953A1
(en)
|
2012-04-20 |
2013-10-24 |
Merus B.V. |
Methods and means for the production of ig-like molecules
|
|
KR20150006000A
(ko)
|
2012-05-01 |
2015-01-15 |
제넨테크, 인크. |
항-pmel17 항체 및 면역접합체
|
|
EP3553089A1
(en)
|
2012-05-10 |
2019-10-16 |
Bioatla, LLC |
Multi-specific monoclonal antibodies
|
|
WO2013170191A1
(en)
|
2012-05-11 |
2013-11-14 |
Genentech, Inc. |
Methods of using antagonists of nad biosynthesis from nicotinamide
|
|
WO2013177062A2
(en)
|
2012-05-21 |
2013-11-28 |
Genentech, Inc. |
Methods for improving safety of blood-brain barrier transport
|
|
EP2852840B1
(en)
|
2012-05-23 |
2019-10-09 |
F.Hoffmann-La Roche Ag |
Selection method for therapeutic agents
|
|
MX2014014162A
(es)
*
|
2012-05-24 |
2015-02-04 |
Hoffmann La Roche |
Anticuerpos multiespecificos.
|
|
AR091462A1
(es)
|
2012-06-15 |
2015-02-04 |
Genentech Inc |
Anticuerpos anti-pcsk9, formulaciones, dosificacion y metodos de uso
|
|
US9890215B2
(en)
|
2012-06-22 |
2018-02-13 |
King's College London |
Vista modulators for diagnosis and treatment of cancer
|
|
CN104619722B
(zh)
|
2012-06-22 |
2022-10-04 |
达特茅斯大学理事会 |
新型vista-ig构建体和vista-ig用于治疗自身免疫性、过敏性和炎性疾病的用途
|
|
SG11201407420RA
(en)
|
2012-07-04 |
2015-02-27 |
Hoffmann La Roche |
Covalently linked antigen-antibody conjugates
|
|
EP2869837B1
(en)
|
2012-07-04 |
2016-09-14 |
F. Hoffmann-La Roche AG |
Anti-theophylline antibodies and methods of use
|
|
MX354303B
(es)
|
2012-07-04 |
2018-02-23 |
Hoffmann La Roche |
Anticuerpos de anti-biotina y metodos de uso.
|
|
PL2870247T3
(pl)
|
2012-07-05 |
2019-10-31 |
Hoffmann La Roche |
Układ ekspresji i wydzielania
|
|
AU2013288932A1
(en)
|
2012-07-09 |
2014-12-11 |
Genentech, Inc. |
Immunoconjugates comprising anti - CD79b antibodies
|
|
BR112015000437A2
(pt)
|
2012-07-09 |
2017-06-27 |
Genentech Inc |
imunoconjugados, formulação farmacêutica, métodos de tratamento e de inbir a proliferação de uma célula
|
|
KR20150027829A
(ko)
|
2012-07-09 |
2015-03-12 |
제넨테크, 인크. |
항-cd22 항체를 포함하는 면역접합체
|
|
CA2874904A1
(en)
|
2012-07-09 |
2014-01-16 |
Genentech, Inc. |
Immunoconjugates comprising anti-cd22 antibodies
|
|
SI3495387T1
(sl)
|
2012-07-13 |
2021-12-31 |
Roche Glycart Ag |
Bispecifična protitelesa proti VEGF/proti ANG-2 in njihova uporaba pri zdravljenju bolezni očesnih žil
|
|
EP2875356A1
(en)
*
|
2012-07-23 |
2015-05-27 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
Method for diagnosing scleroderma
|
|
CA2884704C
(en)
|
2012-09-07 |
2023-04-04 |
Randolph J. Noelle |
Vista modulators for diagnosis and treatment of cancer
|
|
BR112015006824A2
(pt)
|
2012-09-27 |
2017-07-04 |
Merus B V |
anticorpo igg biespecífico, método para produzir um anticorpo igg biespecífico, anticorpo, composição farmacêutica e uso de um anticorpo igg biespecífico
|
|
CA2889638A1
(en)
|
2012-10-31 |
2014-05-08 |
Oncomed Pharmaceuticals, Inc. |
Methods and monitoring of treatment with a dll4 antagonist
|
|
EP2727941A1
(en)
|
2012-11-05 |
2014-05-07 |
MAB Discovery GmbH |
Method for the production of multispecific antibodies
|
|
EP4223770A3
(en)
|
2012-11-05 |
2023-10-18 |
Foundation Medicine, Inc. |
Novel fusion molecules and uses thereof
|
|
WO2014067642A1
(en)
|
2012-11-05 |
2014-05-08 |
Mab Discovery Gmbh |
Method for the production of multispecific antibodies
|
|
EP2727942A1
(en)
|
2012-11-05 |
2014-05-07 |
MAB Discovery GmbH |
Bispecific antibodies against human EGFR, HER2, and HER3
|
|
EP2727943A1
(en)
|
2012-11-05 |
2014-05-07 |
MAB Discovery GmbH |
Trispecific antibodies against human EGFR, HER2 and HER3
|
|
EP2914621B1
(en)
|
2012-11-05 |
2023-06-07 |
Foundation Medicine, Inc. |
Novel ntrk1 fusion molecules and uses thereof
|
|
CN104755500B
(zh)
|
2012-11-08 |
2020-10-02 |
霍夫曼-拉罗奇有限公司 |
结合HER3 β-发夹的HER3抗原结合蛋白
|
|
BR112015010817A8
(pt)
|
2012-11-13 |
2018-01-23 |
Genentech Inc |
anticorpos anti-hemaglutinina isolado, método de tratamento, inibição ou prevenção de infecções, composição, composição farmacêutica, ácido nucleico isolado, célula hospedeira, método de produção de anticorpos e uso do anticorpo anti-hemaglutinina
|
|
CA2891566A1
(en)
*
|
2012-12-05 |
2014-06-12 |
Dutalys Gmbh |
Dual targeting
|
|
CA2898326C
(en)
|
2013-01-18 |
2022-05-17 |
Foundation Medicine, Inc. |
Methods of treating cholangiocarcinoma
|
|
WO2014116749A1
(en)
|
2013-01-23 |
2014-07-31 |
Genentech, Inc. |
Anti-hcv antibodies and methods of using thereof
|
|
WO2014128235A1
(en)
|
2013-02-22 |
2014-08-28 |
F. Hoffmann-La Roche Ag |
Methods of treating cancer and preventing drug resistance
|
|
MX2015010789A
(es)
|
2013-02-26 |
2015-11-26 |
Roche Glycart Ag |
Anticuerpos anti-pcsm.
|
|
JP2016510751A
(ja)
|
2013-03-06 |
2016-04-11 |
ジェネンテック， インコーポレイテッド |
抗がん剤耐性を治療及び予防する方法
|
|
MX2015010777A
(es)
|
2013-03-14 |
2016-04-25 |
Genentech Inc |
Anticuerpos e inmunoconjugados anti-b7-h4.
|
|
WO2014152358A2
(en)
|
2013-03-14 |
2014-09-25 |
Genentech, Inc. |
Combinations of a mek inhibitor compound with an her3/egfr inhibitor compound and methods of use
|
|
US9562099B2
(en)
|
2013-03-14 |
2017-02-07 |
Genentech, Inc. |
Anti-B7-H4 antibodies and immunoconjugates
|
|
EP2968565A2
(en)
|
2013-03-14 |
2016-01-20 |
Genentech, Inc. |
Methods of treating cancer and preventing cancer drug resistance
|
|
BR112015021521A2
(pt)
|
2013-03-15 |
2017-10-10 |
Genentech Inc |
anticorpos anti-crth2 e métodos para seu uso
|
|
MX2015011444A
(es)
|
2013-03-15 |
2015-12-16 |
Genentech Inc |
Composiciones y metodos para el diagnostico y tratamiento del cancer hepatico.
|
|
HK1214533A1
(zh)
|
2013-03-15 |
2016-07-29 |
基因泰克公司 |
治疗癌症和预防癌症耐药性的方法
|
|
MX374811B
(es)
|
2013-03-15 |
2025-03-06 |
Ac Immune Sa |
Anticuerpos anti-tau y métodos de uso.
|
|
UA118028C2
(uk)
|
2013-04-03 |
2018-11-12 |
Рош Глікарт Аг |
Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
|
|
CA2904806C
(en)
|
2013-04-29 |
2021-11-23 |
F. Hoffmann-La Roche Ag |
Human fcrn-binding modified antibodies and methods of use
|
|
TW201920285A
(zh)
|
2013-04-29 |
2019-06-01 |
瑞士商赫孚孟拉羅股份公司 |
遏止FcRn結合之抗IGF-1R抗體及其治療血管性眼疾之用途
|
|
CA2904805A1
(en)
|
2013-04-29 |
2014-11-06 |
F. Hoffmann-La Roche Ag |
Fc-receptor binding modified asymmetric antibodies and methods of use
|
|
SG11201509566RA
(en)
|
2013-05-20 |
2015-12-30 |
Genentech Inc |
Anti-transferrin receptor antibodies and methods of use
|
|
BR112016004450A2
(pt)
|
2013-09-17 |
2017-10-17 |
Genentech Inc |
métodos para tratar uma doença, para aumentar a eficácia de um tratamento, para adiar e/ou prevenir desenvolvimento da reincidência e/ou resistência de uma doença, para aumentar a sensibilidade a um inibidor, para estender o período de sensibilidade a um inibidor e para estender a duração de resposta a um inibidor
|
|
WO2015054670A1
(en)
|
2013-10-11 |
2015-04-16 |
Genentech, Inc. |
Nsp4 inhibitors and methods of use
|
|
BR112016006929A2
(pt)
|
2013-10-11 |
2017-09-19 |
Hoffmann La Roche |
Anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, métodos de preparação de anticorpo, de tratamento de pacientes e de geração de um anticorpo, composição farmacêutica e uso do anticorpo
|
|
US20150147333A1
(en)
|
2013-10-18 |
2015-05-28 |
Genentech, Inc. |
Anti-rspo antibodies and methods of use
|
|
JP6715767B2
(ja)
|
2013-10-23 |
2020-07-01 |
ジェネンテック， インコーポレイテッド |
好酸球性疾患の診断及び治療方法
|
|
LT3071597T
(lt)
|
2013-11-21 |
2020-10-12 |
F. Hoffmann-La Roche Ag |
Antikūnai prieš alfa-sunukleiną ir jų naudojimo būdai
|
|
AR098743A1
(es)
|
2013-12-13 |
2016-06-08 |
Genentech Inc |
Anticuerpos e inmunoconjugados anti-cd33
|
|
BR112016011027A2
(pt)
|
2013-12-20 |
2017-12-05 |
Genentech Inc |
método de produção de um anticorpo, anticorpos, composição farmacêutica, polinucleotídeo, vetor, célula hospedeira, método de tratamento de asma e método de tratamento de um distúrbio
|
|
CR20160270A
(es)
|
2013-12-20 |
2016-09-05 |
Hoffmann La Roche |
ANTICUERPOS ANTI-TAU (pS422) HUMANIZADOS Y MÉTODOS DE UTILIZACIÓN
|
|
US11014987B2
(en)
|
2013-12-24 |
2021-05-25 |
Janssen Pharmaceutics Nv |
Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
|
|
US10273301B2
(en)
|
2013-12-24 |
2019-04-30 |
Janssen Pharmaceutica Nv |
Anti-vista antibodies and fragments
|
|
BR112016014945A2
(pt)
|
2014-01-03 |
2018-01-23 |
F. Hoffmann-La Roche Ag |
conjugado, formulação farmacêutica e uso
|
|
WO2015101586A1
(en)
|
2014-01-03 |
2015-07-09 |
F. Hoffmann-La Roche Ag |
Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles
|
|
EP3089758B1
(en)
|
2014-01-03 |
2021-01-27 |
F.Hoffmann-La Roche Ag |
Covalently linked helicar-anti-helicar antibody conjugates and uses thereof
|
|
PL3092251T3
(pl)
|
2014-01-06 |
2021-08-02 |
F. Hoffmann-La Roche Ag |
Jednowartościowe moduły transportera wahadłowego przez barierę krew-mózg
|
|
CN110903398B
(zh)
|
2014-01-15 |
2023-08-15 |
豪夫迈·罗氏有限公司 |
具有修饰的FCRN和保持的蛋白A结合性质的Fc区变体
|
|
UA122479C2
(uk)
|
2014-01-24 |
2020-11-25 |
Дана-Фарбер Кенсер Інстітьют, Інк. |
Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1)
|
|
WO2015112909A1
(en)
|
2014-01-24 |
2015-07-30 |
Genentech, Inc. |
Methods of using anti-steap1 antibodies and immunoconjugates
|
|
PL3099717T3
(pl)
|
2014-01-31 |
2019-10-31 |
Novartis Ag |
Cząsteczki przeciwciała dla TIM-3 i ich zastosowanie
|
|
NZ723884A
(en)
|
2014-02-08 |
2023-02-24 |
Genentech Inc |
Methods of treating alzheimer’s disease
|
|
TW202239429A
(zh)
|
2014-02-08 |
2022-10-16 |
美商建南德克公司 |
治療阿茲海默症之方法
|
|
SI3105253T1
(sl)
|
2014-02-12 |
2018-10-30 |
F. Hoffmann-La Roche Ag |
Protitelesa anti-Jagged1 in načini njihove uporabe
|
|
JP2017507939A
(ja)
|
2014-02-21 |
2017-03-23 |
ジェネンテック， インコーポレイテッド |
抗ｉｌ−１３／ｉｌ−１７二重特異性抗体及びその使用
|
|
DK3805268T3
(da)
|
2014-02-28 |
2025-01-20 |
Merus Nv |
Antistof, der binder erbb-2 og erbb-3
|
|
CA2941030C
(en)
|
2014-02-28 |
2025-05-13 |
Merus N.V. |
ANTIBODIES THAT BIND TO EGFR AND ERBB3
|
|
EA201691765A1
(ru)
|
2014-03-14 |
2016-12-30 |
Новартис Аг |
Молекулы антител против lag-3 и их применения
|
|
SG11201607519VA
(en)
|
2014-03-14 |
2016-10-28 |
Genentech Inc |
Methods and compositions for secretion of heterologous polypeptides
|
|
CN122399016A
(zh)
|
2014-03-15 |
2026-07-17 |
诺华股份有限公司 |
使用嵌合抗原受体治疗癌症
|
|
US20170107294A1
(en)
|
2014-03-21 |
2017-04-20 |
Nordlandssykehuset Hf |
Anti-cd14 antibodies and uses thereof
|
|
RU2688349C2
(ru)
|
2014-03-21 |
2019-05-21 |
Ф. Хоффманн-Ля Рош Аг |
In vitro прогнозирование времени полужизни антител in vivo
|
|
EP3122900A1
(en)
|
2014-03-24 |
2017-02-01 |
F. Hoffmann-La Roche AG |
Cancer treatment with c-met antagonists and correlation of the latter with hgf expression
|
|
KR20160146747A
(ko)
|
2014-03-31 |
2016-12-21 |
제넨테크, 인크. |
항혈관신생제 및 ox40 결합 효능제를 포함하는 조합 요법
|
|
SG11201607969XA
(en)
|
2014-03-31 |
2016-10-28 |
Genentech Inc |
Anti-ox40 antibodies and methods of use
|
|
SG10202107077QA
(en)
|
2014-04-02 |
2021-07-29 |
Hoffmann La Roche |
Method for detecting multispecific antibody light chain mispairing
|
|
WO2015164615A1
(en)
|
2014-04-24 |
2015-10-29 |
University Of Oslo |
Anti-gluten antibodies and uses thereof
|
|
JP2017522861A
(ja)
|
2014-05-22 |
2017-08-17 |
ジェネンテック， インコーポレイテッド |
抗ｇｐｃ３抗体及びイムノコンジュゲート
|
|
KR20170005016A
(ko)
|
2014-05-23 |
2017-01-11 |
제넨테크, 인크. |
MiT 바이오마커 및 그의 사용 방법
|
|
US10647768B2
(en)
|
2014-05-29 |
2020-05-12 |
Macrogenics, Inc. |
Multi-chain polypeptide-containing tri-specific binding molecules
|
|
JP6997619B2
(ja)
|
2014-06-11 |
2022-01-17 |
キャシー・エイ・グリーン |
液性免疫の抑制または増進のための、ｖｉｓｔａアゴニスト及びｖｉｓｔａアンタゴニストの使用
|
|
MX2016016233A
(es)
|
2014-06-11 |
2017-03-31 |
Genentech Inc |
Anticuerpos anti-lgr5 y sus usos.
|
|
WO2015191986A1
(en)
|
2014-06-13 |
2015-12-17 |
Genentech, Inc. |
Methods of treating and preventing cancer drug resistance
|
|
CN106687476B
(zh)
|
2014-06-26 |
2020-11-13 |
豪夫迈·罗氏有限公司 |
抗brdu抗体及使用方法
|
|
AR100978A1
(es)
|
2014-06-26 |
2016-11-16 |
Hoffmann La Roche |
LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
|
|
TWI693232B
(zh)
|
2014-06-26 |
2020-05-11 |
美商宏觀基因股份有限公司 |
與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
|
|
TW201623329A
(zh)
|
2014-06-30 |
2016-07-01 |
亞佛瑞司股份有限公司 |
針對骨調素截斷變異體的疫苗及單株抗體暨其用途
|
|
HRP20192243T1
(hr)
|
2014-07-03 |
2020-03-06 |
F. Hoffmann - La Roche Ag |
Polipeptidni ekspresijski sustavi
|
|
JP6876601B2
(ja)
|
2014-07-10 |
2021-05-26 |
アフィリス・アクチェンゲゼルシャフトＡｆｆｉｒｉｓ Ａｇ |
ハンチントン病の予防および／または処置における使用のための物質および方法
|
|
EP3166627A1
(en)
|
2014-07-11 |
2017-05-17 |
Genentech, Inc. |
Notch pathway inhibition
|
|
CN106604933B
(zh)
|
2014-07-11 |
2021-08-10 |
文塔纳医疗系统公司 |
抗pd-l1抗体及其诊断用途
|
|
JP6831777B2
(ja)
|
2014-07-21 |
2021-02-17 |
ノバルティス アーゲー |
Ｃｄ３３キメラ抗原受容体を使用する癌の処置
|
|
WO2016014553A1
(en)
|
2014-07-21 |
2016-01-28 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
|
AU2015292744C1
(en)
|
2014-07-21 |
2021-01-21 |
Novartis Ag |
Treatment of cancer using humanized anti-BCMA chimeric antigen receptor
|
|
JP2017528433A
(ja)
|
2014-07-21 |
2017-09-28 |
ノバルティス アーゲー |
低い免疫増強用量のｍＴＯＲ阻害剤とＣＡＲの組み合わせ
|
|
WO2016019300A1
(en)
|
2014-07-31 |
2016-02-04 |
Novartis Ag |
Subset-optimized chimeric antigen receptor-containing t-cells
|
|
EP3180359A1
(en)
|
2014-08-14 |
2017-06-21 |
Novartis AG |
Treatment of cancer using gfr alpha-4 chimeric antigen receptor
|
|
EP3712171A1
(en)
|
2014-08-19 |
2020-09-23 |
Novartis AG |
Treatment of cancer using a cd123 chimeric antigen receptor
|
|
TW201625689A
(zh)
|
2014-09-12 |
2016-07-16 |
建南德克公司 |
抗－ｂ７－ｈ４抗體及免疫結合物
|
|
JP2017531620A
(ja)
|
2014-09-12 |
2017-10-26 |
ジェネンテック， インコーポレイテッド |
システイン操作抗体及びコンジュゲート
|
|
SI3191135T1
(sl)
|
2014-09-12 |
2021-01-29 |
Genentech, Inc. |
Anti-HER2 protitelesa in imunokonjugati
|
|
MA40579A
(fr)
|
2014-09-12 |
2016-03-17 |
Genentech Inc |
Anticorps anti-cll-1 et immunoconjugués
|
|
US10577417B2
(en)
|
2014-09-17 |
2020-03-03 |
Novartis Ag |
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
|
|
CA2957148A1
(en)
|
2014-09-17 |
2016-03-24 |
Genentech, Inc. |
Immunoconjugates comprising anti-her2 antibodies and pyrrolobenzodiazepines
|
|
CA2979671C
(en)
|
2014-09-23 |
2020-03-10 |
Genentech, Inc. |
Methods of using anti-cd79b immunoconjugates
|
|
EA201790719A1
(ru)
|
2014-09-26 |
2017-07-31 |
Макродженикс, Инк. |
Биспецифические моновалентные диатела, которые способны связывать cd19 и cd3, а также их применения
|
|
SG11201702401RA
(en)
|
2014-10-14 |
2017-04-27 |
Novartis Ag |
Antibody molecules to pd-l1 and uses thereof
|
|
JP2017536102A
(ja)
|
2014-10-16 |
2017-12-07 |
ジェネンテック， インコーポレイテッド |
抗アルファ−シヌクレイン抗体及び使用方法
|
|
EP3212233B1
(en)
|
2014-10-31 |
2020-06-24 |
Oncomed Pharmaceuticals, Inc. |
Combination therapy for treatment of disease
|
|
CA2966507A1
(en)
|
2014-11-03 |
2016-05-12 |
Genentech, Inc. |
Methods and biomarkers for predicting efficacy and evaluation of an ox40 agonist treatment
|
|
KR20170086540A
(ko)
|
2014-11-03 |
2017-07-26 |
제넨테크, 인크. |
T 세포 면역 하위세트를 검출하기 위한 검정 및 그의 사용 방법
|
|
WO2016073157A1
(en)
|
2014-11-06 |
2016-05-12 |
Genentech, Inc. |
Anti-ang2 antibodies and methods of use thereof
|
|
PT3215528T
(pt)
|
2014-11-06 |
2019-10-11 |
Hoffmann La Roche |
Variantes da região fc com ligação modificada ao fcrn e métodos de utilização
|
|
RU2713131C1
(ru)
|
2014-11-06 |
2020-02-03 |
Ф. Хоффманн-Ля Рош Аг |
ВАРИАНТЫ Fc-ОБЛАСТИ С МОДИФИЦИРОВАННЫМИ СВОЙСТВАМИ СВЯЗЫВАНИЯ FcRn И БЕЛКА А
|
|
JP6929771B2
(ja)
|
2014-11-10 |
2021-09-01 |
ジェネンテック， インコーポレイテッド |
抗インターロイキン−３３抗体及びその使用
|
|
JP2018500882A
(ja)
|
2014-11-10 |
2018-01-18 |
ジェネンテック， インコーポレイテッド |
腎症の動物モデルおよびそれを治療するための薬剤
|
|
EP3221361B1
(en)
|
2014-11-19 |
2021-04-21 |
Genentech, Inc. |
Anti-transferrin receptor / anti-bace1 multispecific antibodies and methods of use
|
|
JP6779876B2
(ja)
|
2014-11-19 |
2020-11-04 |
ジェネンテック， インコーポレイテッド |
抗トランスフェリン受容体抗体及びその使用方法
|
|
EP3221364B1
(en)
|
2014-11-19 |
2020-12-16 |
Genentech, Inc. |
Antibodies against bace1 and use thereof for neural disease immunotherapy
|
|
SG11201704056XA
(en)
|
2014-11-20 |
2017-06-29 |
Hoffmann La Roche |
Combination therapy of t cell activating bispecific antigen binding molecules cd3 abd folate receptor 1 (folr1) and pd-1 axis binding antagonists
|
|
US20180334490A1
(en)
|
2014-12-03 |
2018-11-22 |
Qilong H. Wu |
Methods for b cell preconditioning in car therapy
|
|
MX2017007136A
(es)
|
2014-12-05 |
2017-12-04 |
Immunext Inc |
Identificacion de vsig8 como el receptor vista putativo y su uso para producir moduladores vista/vsig8.
|
|
MX386587B
(es)
|
2014-12-05 |
2025-03-19 |
Genentech Inc |
ANTICUERPOS ANTI-CD79b Y MÉTODOS DE USO.
|
|
SG11201703750XA
(en)
|
2014-12-10 |
2017-06-29 |
Genentech Inc |
Blood brain barrier receptor antibodies and methods of use
|
|
BR112017011170A2
(pt)
|
2014-12-18 |
2018-02-27 |
Hoffmann La Roche |
método para determinar a citotoxicidade dependente do complemento de uma composição
|
|
MX2017005774A
(es)
|
2014-12-19 |
2017-07-28 |
Chugai Pharmaceutical Co Ltd |
Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso.
|
|
EA201791366A1
(ru)
|
2014-12-19 |
2018-02-28 |
Чугаи Сейяку Кабусики Кайся |
Антитела к c5 и способы их применения
|
|
WO2016115274A1
(en)
*
|
2015-01-14 |
2016-07-21 |
Compass Therapeutics Llc |
Multispecific immunomodulatory antigen-binding constructs
|
|
US20180016327A1
(en)
|
2015-01-22 |
2018-01-18 |
Chugai Seiyaku Kabushiki Kaisha |
A Combination of Two or More Anti-C5 Antibodies and Methods of Use
|
|
CN107250161A
(zh)
|
2015-01-26 |
2017-10-13 |
宏观基因有限公司 |
包含dr5‑结合结构域的多价分子
|
|
CN114773469B
(zh)
|
2015-02-05 |
2025-12-19 |
中外制药株式会社 |
包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il-8-结合抗体及其应用
|
|
HRP20192217T1
(hr)
|
2015-03-06 |
2020-02-21 |
F. Hoffmann - La Roche Ag |
ULTRA-PROČIŠĆENI DsbA I DsbC TE POSTUPCI NJIHOVE IZRADE I UPORABE
|
|
EP3271723A1
(en)
|
2015-03-16 |
2018-01-24 |
F. Hoffmann-La Roche AG |
Methods of detecting and quantifying il-13 and uses in diagnosing and treating th2-associated diseases
|
|
WO2016146833A1
(en)
|
2015-03-19 |
2016-09-22 |
F. Hoffmann-La Roche Ag |
Biomarkers for nad(+)-diphthamide adp ribosyltransferase resistance
|
|
MX2017012805A
(es)
|
2015-04-07 |
2018-04-11 |
Genentech Inc |
Complejo de unión a antígenos con actividad agonista y métodos de uso.
|
|
EP3991748A3
(en)
|
2015-04-07 |
2022-08-24 |
Alector LLC |
Anti-sortilin antibodies and methods of use thereof
|
|
PL3280729T3
(pl)
|
2015-04-08 |
2022-08-22 |
Novartis Ag |
Terapie cd20, terapie cd22 i terapie skojarzone komórką eksprymującą chimeryczny receptor antygenowy (car) cd19
|
|
WO2016172583A1
(en)
|
2015-04-23 |
2016-10-27 |
Novartis Ag |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
|
EP3286315B1
(en)
|
2015-04-24 |
2021-05-26 |
F. Hoffmann-La Roche AG |
Methods of identifying bacteria comprising binding polypeptides
|
|
CN116196414A
(zh)
|
2015-05-11 |
2023-06-02 |
豪夫迈·罗氏有限公司 |
治疗狼疮性肾炎的组合物和方法
|
|
EP3302563A1
(en)
|
2015-05-29 |
2018-04-11 |
H. Hoffnabb-La Roche Ag |
Humanized anti-ebola virus glycoprotein antibodies and methods of use
|
|
HK1249016A1
(zh)
|
2015-06-02 |
2018-10-26 |
豪夫迈‧罗氏有限公司 |
使用抗il-34抗体治疗神经疾病的组合物和方法
|
|
NZ775762A
(en)
|
2015-06-05 |
2025-02-28 |
Genentech Inc |
Anti-tau antibodies and methods of use
|
|
AU2016274585A1
(en)
|
2015-06-08 |
2017-12-14 |
Genentech, Inc. |
Methods of treating cancer using anti-OX40 antibodies
|
|
TWI773646B
(zh)
|
2015-06-08 |
2022-08-11 |
美商宏觀基因股份有限公司 |
結合lag-3的分子和其使用方法
|
|
EP3303397A1
(en)
|
2015-06-08 |
2018-04-11 |
H. Hoffnabb-La Roche Ag |
Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists
|
|
US10017577B2
(en)
|
2015-06-15 |
2018-07-10 |
Genentech, Inc. |
Antibodies and immunoconjugates
|
|
EP3310811B1
(en)
|
2015-06-16 |
2021-06-16 |
Genentech, Inc. |
Anti-cd3 antibodies and methods of use
|
|
TW201718647A
(zh)
|
2015-06-16 |
2017-06-01 |
建南德克公司 |
抗-cll-1抗體及使用方法
|
|
ES3043088T3
(en)
|
2015-06-17 |
2025-11-24 |
Hoffmann La Roche |
Anti-her2 antibodies and methods of use
|
|
EP3722314A1
(en)
|
2015-06-24 |
2020-10-14 |
Janssen Pharmaceutica NV |
Anti-vista antibodies and fragments
|
|
ES2809728T3
(es)
|
2015-06-24 |
2021-03-05 |
Hoffmann La Roche |
Anticuerpos anti-tau(pS422) humanizados y procedimientos de uso
|
|
CN107810420B
(zh)
|
2015-06-25 |
2020-08-14 |
豪夫迈·罗氏有限公司 |
用于测定抗体或配体结合和功能的基于细胞的测定
|
|
WO2017004091A1
(en)
|
2015-06-29 |
2017-01-05 |
Genentech, Inc. |
Type ii anti-cd20 antibody for use in organ transplantation
|
|
ES2878316T3
(es)
|
2015-06-29 |
2021-11-18 |
Ventana Med Syst Inc |
Materiales y procedimientos para realizar ensayos histoquímicos de pro-epirregulina y anfirregulina humanas
|
|
WO2017010874A1
(en)
|
2015-07-10 |
2017-01-19 |
Merus N.V. |
Human cd3 binding antibody
|
|
US20180340025A1
(en)
|
2015-07-29 |
2018-11-29 |
Novartis Ag |
Combination therapies comprising antibody molecules to lag-3
|
|
US20180207273A1
(en)
|
2015-07-29 |
2018-07-26 |
Novartis Ag |
Combination therapies comprising antibody molecules to tim-3
|
|
EP3328418A1
(en)
|
2015-07-29 |
2018-06-06 |
Novartis AG |
Combination therapies comprising antibody molecules to pd-1
|
|
PE20231958A1
(es)
|
2015-07-30 |
2023-12-06 |
Macrogenics Inc |
Moleculas de union a pd-1 y metodos de uso de las mismas
|
|
PE20181336A1
(es)
|
2015-09-18 |
2018-08-21 |
Chugai Pharmaceutical Co Ltd |
Anticuerpos que se unen a interleucina 8 (il-8) y sus usos
|
|
JP6904947B2
(ja)
|
2015-09-22 |
2021-07-21 |
スプリング バイオサイエンス コーポレーション |
抗ｏｘ４０抗体及びその診断用途
|
|
US11339213B2
(en)
|
2015-09-23 |
2022-05-24 |
Mereo Biopharma 5, Inc. |
Methods and compositions for treatment of cancer
|
|
JP6959912B2
(ja)
|
2015-09-23 |
2021-11-05 |
ジェネンテック， インコーポレイテッド |
抗ｖｅｇｆ抗体の最適化変異体
|
|
ES2768957T3
(es)
|
2015-09-24 |
2020-06-24 |
Abvitro Llc |
Composiciones de anticuerpos contra el VIH y métodos de uso
|
|
SG10202007764TA
(en)
|
2015-09-25 |
2020-09-29 |
Genentech Inc |
Anti-tigit antibodies and methods of use
|
|
AR106188A1
(es)
|
2015-10-01 |
2017-12-20 |
Hoffmann La Roche |
Anticuerpos anti-cd19 humano humanizados y métodos de utilización
|
|
CR20180243A
(es)
|
2015-10-02 |
2018-07-31 |
Genentech Inc |
Conjugados de anticuerpo-fármaco de pirrolobenzodiazepina y métodos de uso
|
|
SI3356404T1
(sl)
|
2015-10-02 |
2021-11-30 |
F. Hoffmann-La Roche Ag |
Protitelesa proti PD1 in postopki uporabe
|
|
CN108139394B
(zh)
|
2015-10-02 |
2020-10-30 |
豪夫迈·罗氏有限公司 |
用于确定同时结合的基于细胞的fret测定法
|
|
UA128469C2
(uk)
|
2015-10-08 |
2024-07-24 |
Макродженікс, Інк. |
Спосіб лікування в7-н3-експресуючого раку
|
|
JP7296728B2
(ja)
|
2015-10-23 |
2023-06-23 |
メルス ナムローゼ フェンノートシャップ |
癌の成長を抑制する結合分子
|
|
EP3184547A1
(en)
|
2015-10-29 |
2017-06-28 |
F. Hoffmann-La Roche AG |
Anti-tpbg antibodies and methods of use
|
|
EP4015533A1
(en)
|
2015-10-29 |
2022-06-22 |
F. Hoffmann-La Roche AG |
Anti-variant fc-region antibodies and methods of use
|
|
BR112018007703A2
(pt)
|
2015-10-30 |
2018-11-06 |
Genentech Inc |
anticorpos, ácido nucleico isolado, métodos de produção de um anticorpo e de tratamento de um distúrbio, composição farmacêutica, terapia de combinação e uso do anticorpo
|
|
TW201730211A
(zh)
|
2015-10-30 |
2017-09-01 |
建南德克公司 |
抗因子d抗體及結合物
|
|
EP3178848A1
(en)
|
2015-12-09 |
2017-06-14 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies
|
|
IL313608A
(en)
|
2015-12-09 |
2024-08-01 |
Hoffmann La Roche |
Antibody against CD20 type II to reduce the formation of antibodies against drugs
|
|
CN108367069B
(zh)
|
2015-12-14 |
2022-08-23 |
宏观基因有限公司 |
对于pd-1和ctla-4具有免疫反应性的双特异性分子及其使用方法
|
|
CN108697794A
(zh)
|
2015-12-17 |
2018-10-23 |
诺华股份有限公司 |
C-met抑制剂和抗pd-1抗体分子的组合及其用途
|
|
CN108495651A
(zh)
|
2015-12-17 |
2018-09-04 |
诺华股份有限公司 |
抗pd-1的抗体分子及其用途
|
|
CN108401431B
(zh)
|
2015-12-18 |
2022-01-25 |
中外制药株式会社 |
抗-c5抗体及使用方法
|
|
EA201891420A1
(ru)
|
2015-12-18 |
2019-02-28 |
Чугаи Сейяку Кабусики Кайся |
Антитела к миостатину, полипептиды, содержащие варианты fc-областей, и способы их применения
|
|
PT3393504T
(pt)
|
2015-12-22 |
2025-12-30 |
Novartis Ag |
Recetor de antigénio quimérico (car) de mesotelina e anticorpo contra o inibidor de pd-l1 para utilização combinada em terapia anticancerígena
|
|
EP3405489A1
(en)
|
2016-01-20 |
2018-11-28 |
Genentech, Inc. |
High dose treatments for alzheimer's disease
|
|
EP3851457A1
(en)
|
2016-01-21 |
2021-07-21 |
Novartis AG |
Multispecific molecules targeting cll-1
|
|
US10899836B2
(en)
|
2016-02-12 |
2021-01-26 |
Janssen Pharmaceutica Nv |
Method of identifying anti-VISTA antibodies
|
|
AR108034A1
(es)
|
2016-02-17 |
2018-07-11 |
Macrogenics Inc |
Moléculas de unión a ror1, y métodos de uso de las mismas
|
|
SG11201807489PA
(en)
|
2016-03-04 |
2018-09-27 |
Novartis Ag |
Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
|
|
US11291721B2
(en)
|
2016-03-21 |
2022-04-05 |
Marengo Therapeutics, Inc. |
Multispecific and multifunctional molecules and uses thereof
|
|
EP3432924A1
(en)
|
2016-03-23 |
2019-01-30 |
Novartis AG |
Cell secreted minibodies and uses thereof
|
|
CN108700598A
(zh)
|
2016-03-25 |
2018-10-23 |
豪夫迈·罗氏有限公司 |
多路总抗体和抗体缀合的药物量化测定法
|
|
EP3443004A1
(en)
|
2016-04-14 |
2019-02-20 |
H. Hoffnabb-La Roche Ag |
Anti-rspo3 antibodies and methods of use
|
|
US20230071283A1
(en)
|
2016-04-15 |
2023-03-09 |
Aimee S. Payne |
Compositions and methods for selective protein expression
|
|
EP4656204A3
(en)
|
2016-04-15 |
2026-06-03 |
BioAtla, Inc. |
Anti-axl antibodies, antibody fragments and their immunoconjugates and uses thereof
|
|
CN109069633A
(zh)
|
2016-04-15 |
2018-12-21 |
宏观基因有限公司 |
新颖的b7-h3-结合分子、其抗体药物缀合物及其使用方法
|
|
PE20190115A1
(es)
|
2016-04-15 |
2019-01-16 |
Immunext Inc |
Anticuerpos vista antihumanos y su uso
|
|
WO2017189805A1
(en)
|
2016-04-27 |
2017-11-02 |
Abbvie Inc. |
Methods of treatment of diseases in which il-13 activity is detrimental using anti-il-13 antibodies
|
|
JP6675017B2
(ja)
|
2016-05-02 |
2020-04-01 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
コントースボディ−単鎖標的結合物質
|
|
JP7089483B2
(ja)
|
2016-05-11 |
2022-06-22 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
修飾された抗テネイシン抗体及び使用方法
|
|
EP4122958A1
(en)
|
2016-05-13 |
2023-01-25 |
BioAtla, Inc. |
Anti-ror2 antibodies, antibody fragments, their immunoconjugates and uses thereof
|
|
CA3024465A1
(en)
|
2016-05-17 |
2017-11-23 |
Genentech, Inc. |
Stromal gene signatures for diagnosis and use in immunotherapy
|
|
CN109152843A
(zh)
|
2016-05-20 |
2019-01-04 |
豪夫迈·罗氏有限公司 |
Protac抗体缀合物及其使用方法
|
|
CN109313200B
(zh)
|
2016-05-27 |
2022-10-04 |
豪夫迈·罗氏有限公司 |
用于表征位点特异性抗体-药物缀合物的生物分析性方法
|
|
EP3252078A1
(en)
|
2016-06-02 |
2017-12-06 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
|
|
WO2017210617A2
(en)
|
2016-06-02 |
2017-12-07 |
Porter, David, L. |
Therapeutic regimens for chimeric antigen receptor (car)- expressing cells
|
|
TWI760396B
(zh)
|
2016-06-17 |
2022-04-11 |
日商中外製藥股份有限公司 |
抗肌抑素抗體及使用方法
|
|
CA3026518A1
(en)
|
2016-06-17 |
2017-12-21 |
Genentech, Inc. |
Purification of multispecific antibodies
|
|
JP7133477B2
(ja)
|
2016-06-24 |
2022-09-08 |
ジェネンテック， インコーポレイテッド |
抗ポリユビキチン多重特異性抗体
|
|
EP3484455A2
(en)
|
2016-07-15 |
2019-05-22 |
Novartis AG |
Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
|
|
KR20230100748A
(ko)
|
2016-07-28 |
2023-07-05 |
노파르티스 아게 |
키메라 항원 수용체 및 pd-1 억제제의 조합 요법
|
|
SG11201900885VA
(en)
|
2016-08-01 |
2019-02-27 |
Novartis Ag |
Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule
|
|
US11649285B2
(en)
|
2016-08-03 |
2023-05-16 |
Bio-Techne Corporation |
Identification of VSIG3/VISTA as a novel immune checkpoint and use thereof for immunotherapy
|
|
CN116271014A
(zh)
|
2016-08-05 |
2023-06-23 |
中外制药株式会社 |
用于预防或治疗il-8相关疾病的组合物
|
|
WO2018038046A1
(ja)
|
2016-08-22 |
2018-03-01 |
中外製薬株式会社 |
ヒトｇｐｃ３ポリペプチドを発現する遺伝子改変非ヒト動物
|
|
SG10201607778XA
(en)
|
2016-09-16 |
2018-04-27 |
Chugai Pharmaceutical Co Ltd |
Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
|
|
CN116731197A
(zh)
|
2016-09-19 |
2023-09-12 |
豪夫迈·罗氏有限公司 |
基于补体因子的亲和层析
|
|
TWI787203B
(zh)
|
2016-09-23 |
2022-12-21 |
美商建南德克公司 |
Il-13拮抗劑用於治療異位性皮炎之用途
|
|
EP3515951B1
(en)
|
2016-09-23 |
2024-02-28 |
Merus N.V. |
Binding molecules that modulate a biological activity expressed by a cell
|
|
JP7050770B2
(ja)
|
2016-10-05 |
2022-04-08 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
抗体薬物コンジュゲートの調製方法
|
|
JP7467117B2
(ja)
|
2016-10-07 |
2024-04-15 |
ノバルティス アーゲー |
癌の治療のためのキメラ抗原受容体
|
|
EP3532091A2
(en)
|
2016-10-29 |
2019-09-04 |
H. Hoffnabb-La Roche Ag |
Anti-mic antibidies and methods of use
|
|
EP3541843A1
(en)
|
2016-11-15 |
2019-09-25 |
Genentech, Inc. |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
|
|
TW201829463A
(zh)
|
2016-11-18 |
2018-08-16 |
瑞士商赫孚孟拉羅股份公司 |
抗hla-g抗體及其用途
|
|
JOP20190100A1
(ar)
|
2016-11-19 |
2019-05-01 |
Potenza Therapeutics Inc |
بروتينات ربط مولد ضد مضاد لـ gitr وطرق استخدامها
|
|
EP3551655A2
(en)
|
2016-12-07 |
2019-10-16 |
Genentech, Inc. |
Anti-tau antibodies and methods of their use
|
|
EP3551220B1
(en)
|
2016-12-07 |
2025-01-29 |
Genentech, Inc. |
Anti-tau antibodies and methods of use
|
|
WO2018108759A1
(en)
|
2016-12-13 |
2018-06-21 |
F. Hoffmann-La Roche Ag |
Method to determine the presence of a target antigen in a tumor sample
|
|
JP7125400B2
(ja)
|
2016-12-19 |
2022-08-24 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
標的化４－１ｂｂ（ｃｄ１３７）アゴニストとの併用療法
|
|
KR102692708B1
(ko)
|
2016-12-20 |
2024-08-07 |
에프. 호프만-라 로슈 아게 |
항-cd20/항-cd3 이중특이성 항체 및 4-1bb(cd137) 작용물질의 병용 요법
|
|
EP3559248B2
(en)
|
2016-12-21 |
2024-11-20 |
F. Hoffmann-La Roche AG |
In vitro glycoengineering of antibodies
|
|
MX2019007411A
(es)
|
2016-12-21 |
2019-08-29 |
Hoffmann La Roche |
Reuso de enzimas en glucomanipulacion in vitro de anticuerpos.
|
|
CN110088625B
(zh)
|
2016-12-21 |
2023-11-03 |
豪夫迈·罗氏有限公司 |
用于确定抗体或配体结合和功能的测定法
|
|
MX2019006123A
(es)
|
2016-12-21 |
2019-08-12 |
Hoffmann La Roche |
Metodo para glicomanipulacion in vitro de anticuerpos.
|
|
BR112019012950A2
(pt)
|
2016-12-23 |
2019-11-26 |
Macrogenics, Inc. |
molécula de ligação a adam9, composição farmacêutica, uso da molécula de ligação a adam9 e método para tratar uma doença ou condição associada ou caracterizada pela expressão de adam9 em um indivíduo
|
|
US11535662B2
(en)
|
2017-01-26 |
2022-12-27 |
Novartis Ag |
CD28 compositions and methods for chimeric antigen receptor therapy
|
|
CN116715775A
(zh)
|
2017-02-10 |
2023-09-08 |
豪夫迈·罗氏有限公司 |
抗类胰蛋白酶抗体、其组合物及其用途
|
|
WO2018151820A1
(en)
|
2017-02-16 |
2018-08-23 |
Elstar Therapeutics, Inc. |
Multifunctional molecules comprising a trimeric ligand and uses thereof
|
|
BR112019017628A2
(pt)
|
2017-02-24 |
2020-07-07 |
Macrogenics, Inc. |
molécula de ligação a cd137 x ta, composições farmacêuticas, uso da molécula de ligação a cd137 x ta, molécula de ligação a cd137, uso da molécula de ligação a cd137, molécula de ligação a her2/neu, uso da molécula de ligação a her2/neu, e uso de uma composição
|
|
WO2018160731A1
(en)
|
2017-02-28 |
2018-09-07 |
Novartis Ag |
Shp inhibitor compositions and uses for chimeric antigen receptor therapy
|
|
JP7216006B2
(ja)
|
2017-03-22 |
2023-01-31 |
ジェネンテック， インコーポレイテッド |
ヒドロゲル架橋ヒアルロン酸プロドラッグ組成物及び方法
|
|
EP3600442A1
(en)
|
2017-03-22 |
2020-02-05 |
Genentech, Inc. |
Optimized antibody compositions for treatment of ocular disorders
|
|
CN117205311A
(zh)
|
2017-03-28 |
2023-12-12 |
基因泰克公司 |
治疗神经退行性疾病的方法
|
|
JP7737220B2
(ja)
|
2017-03-31 |
2025-09-10 |
メルス ナムローゼ フェンノートシャップ |
ＮＲＧ１融合遺伝子を有する細胞の処置における使用のためのＥｒｂＢ－２及びＥｒｂＢ３結合二重特異性抗体
|
|
MX2019011658A
(es)
|
2017-03-31 |
2019-11-18 |
Merus Nv |
Agente que se dirige al receptor 2 del factor de crecimiento epidermico humano (erbb-2) y anticuerpo biespecifico con sitios de union a antigeno que se unen a un epitopo sobre una parte extracelular de erbb-2 y el receptor 3 del factor de crecimiento epidermico humano (erbb-3), para el tratamiento de un individuo con un tumor positivo para erbb-2, erbb-2/erbb-3.
|
|
PE20200010A1
(es)
|
2017-04-03 |
2020-01-06 |
Hoffmann La Roche |
Anticuerpos que se unen a steap-1
|
|
UA128387C2
(uk)
|
2017-04-05 |
2024-07-03 |
Ф. Хоффманн-Ля Рош Аг |
Антитіло до lag3
|
|
TW201841656A
(zh)
|
2017-04-21 |
2018-12-01 |
美商建南德克公司 |
Ｋｌｋ５拮抗劑用於治療疾病之用途
|
|
EP3615068A1
(en)
|
2017-04-28 |
2020-03-04 |
Novartis AG |
Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
|
|
EP3615055A1
(en)
|
2017-04-28 |
2020-03-04 |
Novartis AG |
Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
|
|
EP3625264B9
(en)
|
2017-05-17 |
2023-10-25 |
Merus N.V. |
Combination of an erbb-2/erbb-3 bispecific antibody with endocrine therapy for breast cancer
|
|
EP3630836A1
(en)
|
2017-05-31 |
2020-04-08 |
Elstar Therapeutics, Inc. |
Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof
|
|
JP2020521791A
(ja)
|
2017-06-02 |
2020-07-27 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
がんの治療のためのｉｉ型抗ｃｄ２０抗体及び抗ｃｄ２０／ｃｄ３０二重特異性抗体
|
|
MX2019015885A
(es)
|
2017-06-22 |
2020-09-10 |
Novartis Ag |
Moleculas de anticuerpo que se unen a cd73 y usos de las mismas.
|
|
CN111050791A
(zh)
|
2017-06-27 |
2020-04-21 |
诺华股份有限公司 |
用于抗tim-3抗体的给药方案及其用途
|
|
SG10201913147WA
(en)
|
2017-07-11 |
2020-02-27 |
Compass Therapeutics Llc |
Agonist antibodies that bind human cd137 and uses thereof
|
|
GB201711208D0
(en)
|
2017-07-12 |
2017-08-23 |
Iontas Ltd |
Ion channel inhibitors
|
|
WO2019018730A1
(en)
|
2017-07-20 |
2019-01-24 |
Novartis Ag |
DOSAGE REGIMES FOR ANTI-LAG3 ANTIBODIES AND USES THEREOF
|
|
EP3658589B1
(en)
|
2017-07-26 |
2023-09-27 |
Forty Seven, Inc. |
Anti-sirp-alpha antibodies and related methods
|
|
RS66708B9
(sr)
|
2017-08-09 |
2025-08-29 |
Merus Nv |
Antitela koja se vezuju za egfr i cmet
|
|
WO2019035938A1
(en)
|
2017-08-16 |
2019-02-21 |
Elstar Therapeutics, Inc. |
MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
|
|
WO2019077092A1
(en)
|
2017-10-20 |
2019-04-25 |
F. Hoffmann-La Roche Ag |
METHOD FOR GENERATING MULTISPECIFIC ANTIBODIES FROM MONOSPECIFIC ANTIBODIES
|
|
IL274071B2
(en)
|
2017-10-30 |
2025-10-01 |
Hoffmann La Roche |
Method for generating in vivo multispecific antibodies from monospecific antibodies
|
|
US11718679B2
(en)
|
2017-10-31 |
2023-08-08 |
Compass Therapeutics Llc |
CD137 antibodies and PD-1 antagonists and uses thereof
|
|
US20210179709A1
(en)
|
2017-10-31 |
2021-06-17 |
Novartis Ag |
Anti-car compositions and methods
|
|
BR112020008031A2
(pt)
|
2017-11-01 |
2020-10-27 |
F. Hoffmann-La Roche Ag |
anticorpo multiespecíficos, método para a preparação do anticorpo multiespecífico, conjunto de ácidos nucleicos, vetor de expressão, célula hospedeira e composição farmacêutica
|
|
EP3704155A2
(en)
|
2017-11-01 |
2020-09-09 |
F. Hoffmann-La Roche AG |
Combination therapy with targeted ox40 agonists
|
|
CN111295392A
(zh)
|
2017-11-01 |
2020-06-16 |
豪夫迈·罗氏有限公司 |
Compbody–多价靶结合物
|
|
EP4640703A3
(en)
|
2017-11-14 |
2026-04-08 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-c1s antibodies and methods of use
|
|
MX2020004756A
(es)
|
2017-11-16 |
2020-08-20 |
Novartis Ag |
Terapias de combinacion.
|
|
EP3713961A2
(en)
|
2017-11-20 |
2020-09-30 |
Compass Therapeutics LLC |
Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof
|
|
WO2019108065A1
(en)
|
2017-12-01 |
2019-06-06 |
Merus N.V. |
Use of bispecific antibody and il-15 for combination therapy
|
|
US11795226B2
(en)
|
2017-12-12 |
2023-10-24 |
Macrogenics, Inc. |
Bispecific CD16-binding molecules and their use in the treatment of disease
|
|
PE20201149A1
(es)
|
2017-12-21 |
2020-10-26 |
Hoffmann La Roche |
Anticuerpos de union a hla-a2/wt1
|
|
US20190211098A1
(en)
|
2017-12-22 |
2019-07-11 |
Genentech, Inc. |
Use of pilra binding agents for treatment of a disease
|
|
CN111886246B
(zh)
|
2017-12-29 |
2024-12-17 |
艾莱克特有限责任公司 |
抗tmem106b抗体及其使用方法
|
|
KR20240134250A
(ko)
|
2018-01-04 |
2024-09-06 |
아이코닉 테라퓨틱스, 인코포레이티드 |
항-조직 인자 항체, 항체-약물 결합체, 및 관련 방법
|
|
US12247060B2
(en)
|
2018-01-09 |
2025-03-11 |
Marengo Therapeutics, Inc. |
Calreticulin binding constructs and engineered T cells for the treatment of diseases
|
|
JP2021511793A
(ja)
|
2018-01-31 |
2021-05-13 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
Ｌａｇ３に結合する抗原結合部位を含む二重特異性抗体
|
|
AU2019215031C1
(en)
|
2018-01-31 |
2026-02-26 |
Novartis Ag |
Combination therapy using a chimeric antigen receptor
|
|
EP3746476A1
(en)
|
2018-01-31 |
2020-12-09 |
Alector LLC |
Anti-ms4a4a antibodies and methods of use thereof
|
|
JP2021511782A
(ja)
|
2018-01-31 |
2021-05-13 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
安定化された免疫グロブリンドメイン
|
|
EP3746484A4
(en)
|
2018-01-31 |
2021-11-17 |
Alector LLC |
ANTI-MS4A6A ANTIBODY AND METHOD OF USING THEREOF
|
|
US11787857B2
(en)
|
2018-02-02 |
2023-10-17 |
Bio-Techne Corporation |
Compounds that modulate the interaction of VISTA and VSIG3 and methods of making and using
|
|
CN111699004A
(zh)
|
2018-02-06 |
2020-09-22 |
豪夫迈·罗氏有限公司 |
眼科疾病的治疗
|
|
KR20220098056A
(ko)
|
2018-02-09 |
2022-07-08 |
제넨테크, 인크. |
비만 세포 매개 염증성 질환에 대한 치료 및 진단 방법
|
|
TWI829667B
(zh)
|
2018-02-09 |
2024-01-21 |
瑞士商赫孚孟拉羅股份公司 |
結合gprc5d之抗體
|
|
CN111787949A
(zh)
|
2018-02-15 |
2020-10-16 |
宏观基因有限公司 |
变体cd3-结合结构域及其在用于治疗疾病的组合疗法中的用途
|
|
TWI841551B
(zh)
|
2018-03-13 |
2024-05-11 |
瑞士商赫孚孟拉羅股份公司 |
使用靶向4-1bb (cd137)之促效劑的組合療法
|
|
PL3765489T3
(pl)
|
2018-03-13 |
2025-02-10 |
F. Hoffmann-La Roche Ag |
Terapeutyczne połączenie agonistów 4-1BB z przeciwciałami anty-CD20
|
|
EP3765516A2
(en)
|
2018-03-14 |
2021-01-20 |
Elstar Therapeutics, Inc. |
Multifunctional molecules and uses thereof
|
|
US20200040103A1
(en)
|
2018-03-14 |
2020-02-06 |
Genentech, Inc. |
Anti-klk5 antibodies and methods of use
|
|
EP3765517A1
(en)
|
2018-03-14 |
2021-01-20 |
Elstar Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
|
TWI827585B
(zh)
|
2018-03-15 |
2024-01-01 |
日商中外製藥股份有限公司 |
對茲卡病毒具有交叉反應性的抗登革病毒抗體及其使用方法
|
|
JP2021519073A
(ja)
|
2018-03-29 |
2021-08-10 |
ジェネンテック， インコーポレイテッド |
哺乳動物細胞におけるラクトジェニック活性の制御
|
|
US20210147547A1
(en)
|
2018-04-13 |
2021-05-20 |
Novartis Ag |
Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
|
|
AR114789A1
(es)
|
2018-04-18 |
2020-10-14 |
Hoffmann La Roche |
Anticuerpos anti-hla-g y uso de los mismos
|
|
AR115052A1
(es)
|
2018-04-18 |
2020-11-25 |
Hoffmann La Roche |
Anticuerpos multiespecíficos y utilización de los mismos
|
|
US20210047405A1
(en)
|
2018-04-27 |
2021-02-18 |
Novartis Ag |
Car t cell therapies with enhanced efficacy
|
|
WO2019219721A1
(en)
|
2018-05-18 |
2019-11-21 |
F. Hoffmann-La Roche Ag |
Targeted intracellular delivery of large nucleic acids
|
|
CN112384534A
(zh)
|
2018-05-21 |
2021-02-19 |
指南针制药有限责任公司 |
用于增强nk细胞对靶细胞的杀死的组合物和方法
|
|
WO2019226658A1
(en)
|
2018-05-21 |
2019-11-28 |
Compass Therapeutics Llc |
Multispecific antigen-binding compositions and methods of use
|
|
US20210213063A1
(en)
|
2018-05-25 |
2021-07-15 |
Novartis Ag |
Combination therapy with chimeric antigen receptor (car) therapies
|
|
CR20200566A
(es)
|
2018-05-25 |
2021-02-19 |
Alector Llc |
Anticuerpos anti-sirpa y metodos de utilización de los mismos
|
|
WO2019232244A2
(en)
|
2018-05-31 |
2019-12-05 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
|
EP3805400A4
(en)
|
2018-06-04 |
2022-06-29 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule showing changed half-life in cytoplasm
|
|
IL279367B2
(en)
|
2018-06-13 |
2026-05-01 |
Novartis Ag |
BCMA chimeric antigen receptors and their uses
|
|
CN112513081A
(zh)
|
2018-06-14 |
2021-03-16 |
生物蛋白有限公司 |
多重特异性抗体构建体
|
|
CA3104295A1
(en)
|
2018-06-19 |
2019-12-26 |
Atarga, Llc |
Antibody molecules to complement component 5 and uses thereof
|
|
AU2019293589A1
(en)
|
2018-06-29 |
2021-01-21 |
Alector Llc |
Anti-SIRP-beta1 antibodies and methods of use thereof
|
|
WO2020010250A2
(en)
|
2018-07-03 |
2020-01-09 |
Elstar Therapeutics, Inc. |
Anti-tcr antibody molecules and uses thereof
|
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
|
SMT202300110T1
(it)
|
2018-07-13 |
2023-05-12 |
Alector Llc |
Anticorpi anti-sortilina e relativi metodi di uso
|
|
JP7072715B2
(ja)
|
2018-07-20 |
2022-05-20 |
サーフィス オンコロジー インコーポレイテッド |
抗ｃｄ１１２ｒ組成物及び方法
|
|
JP2021531306A
(ja)
|
2018-07-25 |
2021-11-18 |
アドバンスド アクセラレーター アプリケーションズ エスエー |
神経内分泌腫瘍の処置の方法
|
|
US12172106B2
(en)
|
2018-08-09 |
2024-12-24 |
Regeneron Pharmaceuticals, Inc. |
Methods for assessing binding affinity of an antibody variant to the neonatal Fc receptor
|
|
MX2021001431A
(es)
|
2018-08-10 |
2021-05-12 |
Chugai Pharmaceutical Co Ltd |
Molecula de union al antigeno anti grupo de diferenciacion 137 (cd137) y su uso.
|
|
GB201814281D0
(en)
|
2018-09-03 |
2018-10-17 |
Femtogenix Ltd |
Cytotoxic agents
|
|
CA3112043A1
(en)
|
2018-09-10 |
2020-03-19 |
Mirati Therapeutics, Inc. |
Combination therapies
|
|
AU2019365238A1
(en)
|
2018-10-24 |
2021-05-13 |
F. Hoffmann-La Roche Ag |
Conjugated chemical inducers of degradation and methods of use
|
|
CN119033684A
(zh)
|
2018-10-29 |
2024-11-29 |
豪夫迈·罗氏有限公司 |
抗体制剂
|
|
JP7497351B2
(ja)
|
2018-11-13 |
2024-06-10 |
コンパス セラピューティクス リミテッド ライアビリティ カンパニー |
チェックポイント分子に対する多重特異性結合性構築物およびその使用
|
|
BR112021010908A2
(pt)
|
2018-12-06 |
2021-08-31 |
Genentech, Inc. |
Método para tratamento de linfoma difuso de grandes células b, kit e imunoconjugado
|
|
EP3894427A1
(en)
|
2018-12-10 |
2021-10-20 |
Genentech, Inc. |
Photocrosslinking peptides for site specific conjugation to fc-containing proteins
|
|
AU2019402189B2
(en)
|
2018-12-20 |
2023-04-13 |
Novartis Ag |
Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
|
US20210386763A1
(en)
|
2018-12-20 |
2021-12-16 |
Novartis Ag |
Pharmaceutical combinations
|
|
CN113366018A
(zh)
|
2018-12-20 |
2021-09-07 |
美勒斯公司 |
用于治疗疾病的CLEC12AxCD3双特异性抗体和方法
|
|
WO2020127873A1
(en)
|
2018-12-21 |
2020-06-25 |
F. Hoffmann-La Roche Ag |
Antibody that binds to vegf and il-1beta and methods of use
|
|
SG11202102859TA
(en)
|
2018-12-21 |
2021-04-29 |
Hoffmann La Roche |
Antibodies binding to cd3
|
|
EP3902560A1
(en)
|
2018-12-28 |
2021-11-03 |
F. Hoffmann-La Roche AG |
A peptide-mhc-i-antibody fusion protein for therapeutic use in a patient with amplified immune response
|
|
WO2020153467A1
(ja)
|
2019-01-24 |
2020-07-30 |
中外製薬株式会社 |
新規がん抗原及びそれらの抗原に対する抗体
|
|
GB201901197D0
(en)
|
2019-01-29 |
2019-03-20 |
Femtogenix Ltd |
G-A Crosslinking cytotoxic agents
|
|
MX2021009769A
(es)
|
2019-02-14 |
2021-09-08 |
Merus Nv |
Produccion de composiciones que comprenden dos o mas anticuerpos.
|
|
SG11202108737RA
(en)
|
2019-02-14 |
2021-09-29 |
Merus Nv |
Combinations of binding moieties that bind egfr, her2 and her3.
|
|
CA3123519A1
(en)
|
2019-02-15 |
2020-08-20 |
Novartis Ag |
Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
EP3924054B1
(en)
|
2019-02-15 |
2025-04-02 |
Novartis AG |
3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
US10871640B2
(en)
|
2019-02-15 |
2020-12-22 |
Perkinelmer Cellular Technologies Germany Gmbh |
Methods and systems for automated imaging of three-dimensional objects
|
|
JP7579795B2
(ja)
|
2019-02-21 |
2024-11-08 |
マレンゴ・セラピューティクス，インコーポレーテッド |
ＮＫｐ３０に結合する抗体分子およびその使用
|
|
AU2020226893B2
(en)
|
2019-02-21 |
2025-02-27 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to T cell related cancer cells and uses thereof
|
|
SG11202109122SA
(en)
|
2019-02-21 |
2021-09-29 |
Marengo Therapeutics Inc |
Anti-tcr antibody molecules and uses thereof
|
|
WO2020172598A1
(en)
|
2019-02-21 |
2020-08-27 |
Elstar Therapeutics, Inc. |
Multifunctional molecules that bind to t cells and uses thereof to treat autoimmune disorders
|
|
SG11202109056TA
(en)
|
2019-02-21 |
2021-09-29 |
Marengo Therapeutics Inc |
Multifunctional molecules that bind to calreticulin and uses thereof
|
|
EP3927371A1
(en)
|
2019-02-22 |
2021-12-29 |
Novartis AG |
Combination therapies of egfrviii chimeric antigen receptors and pd-1 inhibitors
|
|
MA55296A
(fr)
|
2019-03-14 |
2022-03-23 |
Hoffmann La Roche |
Traitement du cancer avec des anticorps bispécifiques de her2xcd3 en combinaison avec un mab anti-her2
|
|
TWI915311B
(zh)
|
2019-03-29 |
2026-02-21 |
荷蘭商美勒斯公司 |
Cd3結合分子
|
|
PH12021552414A1
(en)
|
2019-03-29 |
2022-07-25 |
Atarga Llc |
Anti fgf23 antibody
|
|
US12392777B2
(en)
|
2019-04-02 |
2025-08-19 |
National Research Council Of Canada |
Antibody variants with pH-dependent antigen binding for selective targeting of solid tumors
|
|
KR20220002967A
(ko)
|
2019-04-19 |
2022-01-07 |
제넨테크, 인크. |
항 mertk 항체 및 이의 사용 방법
|
|
AU2020268896B2
(en)
|
2019-05-03 |
2024-11-28 |
F. Hoffmann-La Roche Ag |
Methods of reducing the enzymatic hydrolysis activity rate in a composition obtained from a purification platform
|
|
EP3966238A2
(en)
|
2019-05-09 |
2022-03-16 |
Merus N.V. |
Variant domains for multimerizing proteins and separation thereof
|
|
BR112021022815A2
(pt)
|
2019-05-14 |
2021-12-28 |
Genentech Inc |
Métodos para tratar linfoma folicular, kits, imunoconjugados e polatuzumabe vedotina
|
|
CA3137649A1
(en)
|
2019-05-15 |
2020-11-19 |
Chugai Seiyaku Kabushiki Kaisha |
An antigen-binding molecule, a pharmaceutical composition, and a method
|
|
WO2020243021A2
(en)
|
2019-05-24 |
2020-12-03 |
Foundation Medicine, Inc. |
Ntrk fusion molecules and uses thereof
|
|
JP7082245B2
(ja)
|
2019-06-10 |
2022-06-07 |
中外製薬株式会社 |
サイトカイン阻害剤と組み合わせて使用するための抗ｔ細胞抗原結合分子
|
|
TWI877170B
(zh)
|
2019-06-11 |
2025-03-21 |
美商阿列克特有限責任公司 |
抗揀選蛋白抗體之使用方法
|
|
MX2021015823A
(es)
|
2019-06-26 |
2022-02-03 |
Hoffmann La Roche |
Lineas celulares de mamifero con inactivacion del gen sirtuina-1 (sirt-1).
|
|
AR119393A1
(es)
|
2019-07-15 |
2021-12-15 |
Hoffmann La Roche |
Anticuerpos que se unen a nkg2d
|
|
JP2022543553A
(ja)
|
2019-07-31 |
2022-10-13 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
Ｇｐｒｃ５ｄに結合する抗体
|
|
PH12022550239A1
(en)
|
2019-07-31 |
2022-12-19 |
Alector Llc |
Anti-ms4a4a antibodies and methods of use thereof
|
|
WO2021018925A1
(en)
|
2019-07-31 |
2021-02-04 |
F. Hoffmann-La Roche Ag |
Antibodies binding to gprc5d
|
|
JP7536085B2
(ja)
|
2019-08-19 |
2024-08-19 |
メルス ナムローゼ フェンノートシャップ |
Ｌｇｒ５及びｅｇｆｒに結合する抗体とトポイソメラーゼｉ阻害剤との組合せを用いる癌の治療
|
|
ES3064633T3
(en)
|
2019-09-12 |
2026-04-28 |
Hoffmann La Roche |
Compositions and methods of treating lupus nephritis
|
|
AU2020349509A1
(en)
|
2019-09-18 |
2022-03-31 |
Genentech, Inc. |
Anti-KLK7 antibodies, anti-KLK5 antibodies, multispecific anti-KLK5/KLK7 antibodies, and methods of use
|
|
MX2022003266A
(es)
|
2019-09-20 |
2022-04-11 |
Genentech Inc |
Dosis para anticuerpos anti-triptasa.
|
|
US12590171B2
(en)
|
2019-09-27 |
2026-03-31 |
Nanjing GenScript Biotech Co., Ltd. |
Anti-VHH domain antibodies and use thereof
|
|
CR20220166A
(es)
|
2019-10-18 |
2022-06-15 |
Genentech Inc |
Métodos para usar inmunoconjugados anti-cd79b para tratar linfoma difuso de linfocitos b grandes
|
|
CN114786679A
(zh)
|
2019-10-21 |
2022-07-22 |
诺华股份有限公司 |
具有维奈托克和tim-3抑制剂的组合疗法
|
|
WO2021079195A1
(en)
|
2019-10-21 |
2021-04-29 |
Novartis Ag |
Tim-3 inhibitors and uses thereof
|
|
US20220396839A1
(en)
|
2019-11-12 |
2022-12-15 |
Foundation Medicine, Inc. |
Methods of detecting a fusion gene encoding a neoantigen
|
|
CN114641270A
(zh)
|
2019-11-15 |
2022-06-17 |
豪夫迈·罗氏有限公司 |
防止水性蛋白质溶液中可见颗粒的形成
|
|
WO2021108661A2
(en)
|
2019-11-26 |
2021-06-03 |
Novartis Ag |
Chimeric antigen receptors and uses thereof
|
|
CR20220330A
(es)
|
2019-12-13 |
2022-08-04 |
Genentech Inc |
Anticuerpos anti-ly6g6d y métodos de uso.
|
|
BR112022012010A2
(pt)
|
2019-12-18 |
2022-08-30 |
Hoffmann La Roche |
Anticorpos, ácido nucleico isolado, célula hospedeira, formulação farmacêutica, uso do anticorpo, método de produção de um anticorpo, método de tratamento de um indivíduo que tem câncer e método de tratamento de um indivíduo que tem uma doença inflamatória ou autoimune
|
|
CN114828965B
(zh)
|
2019-12-18 |
2025-09-05 |
豪夫迈·罗氏有限公司 |
与hla-a2/mage-a4结合的抗体
|
|
US20230057071A1
(en)
|
2019-12-20 |
2023-02-23 |
Novartis Ag |
Combination of anti tim-3 antibody mbg453 and anti tgf-beta antibody nis793, with or without decitabine or the anti pd-1 antibody spartalizumab, for treating myelofibrosis and myelodysplastic syndrome
|
|
KR102426802B1
(ko)
*
|
2019-12-23 |
2022-07-28 |
한국프라임제약주식회사 |
혈관내피성장인자 수용체 융합단백질을 포함하는 신생혈관형성 관련 질환의 예방 및 치료를 위한 약학조성물
|
|
CN115515678A
(zh)
|
2019-12-23 |
2022-12-23 |
基因泰克公司 |
载脂蛋白l1特异性抗体及其使用方法
|
|
MY202559A
(en)
|
2019-12-27 |
2024-05-08 |
Chugai Pharmaceutical Co Ltd |
Anti-ctla-4 antibody and use thereof
|
|
EP4084821A4
(en)
|
2020-01-03 |
2024-04-24 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to cd33 and uses thereof
|
|
WO2021138474A2
(en)
|
2020-01-03 |
2021-07-08 |
Marengo Therapeutics, Inc. |
Anti-tcr antibody molecules and uses thereof
|
|
AU2021208515A1
(en)
|
2020-01-15 |
2022-08-04 |
F. Hoffmann-La Roche Ag |
Methods to decrease impurities from recombinant protein manufacturing processes
|
|
EP4090335A1
(en)
|
2020-01-17 |
2022-11-23 |
Novartis AG |
Combination comprising a tim-3 inhibitor and a hypomethylating agent for use in treating myelodysplastic syndrome or chronic myelomonocytic leukemia
|
|
CN115298322A
(zh)
|
2020-01-17 |
2022-11-04 |
贝克顿迪金森公司 |
用于单细胞分泌组学的方法和组合物
|
|
EP4097131A1
(en)
|
2020-01-29 |
2022-12-07 |
Merus N.V. |
Means and method for modulating immune cell engaging effects
|
|
IL295382B1
(en)
|
2020-02-12 |
2026-08-01 |
Chugai Seiyaku Kk |
Anti-CD137 antigen-binding molecule for use in cancer treatment
|
|
JP7745556B2
(ja)
|
2020-02-21 |
2025-09-29 |
マクロジェニクス，インコーポレーテッド |
Ｃｄ１３７結合分子及びその使用
|
|
IL295878A
(en)
|
2020-02-27 |
2022-10-01 |
Novartis Ag |
Methods for producing cells expressing a chimeric antigen receptor
|
|
EP4118114A1
(en)
|
2020-03-13 |
2023-01-18 |
Genentech, Inc. |
Anti-interleukin-33 antibodies and uses thereof
|
|
CA3169626A1
(en)
|
2020-03-19 |
2021-09-23 |
Genentech, Inc. |
Isoform-selective anti-tgf-beta antibodies and methods of use
|
|
CA3169967A1
(en)
|
2020-03-24 |
2021-09-30 |
Genentech, Inc. |
Tie2-binding agents and methods of use
|
|
US12098365B2
(en)
|
2020-03-26 |
2024-09-24 |
Genentech, Inc. |
Modified mammalian cells
|
|
JP7674383B2
(ja)
|
2020-03-30 |
2025-05-09 |
エフ． ホフマン－ラ ロシュ アーゲー |
Ｖｅｇｆ及びｐｄｇｆ－ｂに結合する抗体及び使用方法
|
|
MX2022013198A
(es)
|
2020-04-24 |
2022-11-14 |
Genentech Inc |
Metodos de uso de inmunoconjugados anti-cd79b.
|
|
AU2021261420A1
(en)
|
2020-04-24 |
2022-12-01 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to T cell related cancer cells and uses thereof
|
|
CN116731189A
(zh)
|
2020-04-24 |
2023-09-12 |
美勒斯公司 |
使用结合lgr5及egfr的抗体的癌症治疗
|
|
JP2023527962A
(ja)
|
2020-05-03 |
2023-07-03 |
レヴィーナ （スジョウ） バイオファーマ カンパニー， リミテッド |
抗ｔｒｏｐ２抗体を含む抗体薬物複合体（ａｄｃ）、かかるａｄｃを含む組成物、ならびにそれらを作製および使用する方法
|
|
KR20230010251A
(ko)
|
2020-05-13 |
2023-01-18 |
보넘 테라퓨틱스, 인크. |
단백질 복합체의 조성물 및 그의 사용 방법
|
|
CN115605184A
(zh)
|
2020-05-15 |
2023-01-13 |
豪夫迈·罗氏有限公司（Ch） |
防止胃肠外蛋白质溶液中的可见颗粒形成
|
|
JP2023525898A
(ja)
|
2020-05-19 |
2023-06-19 |
エフ． ホフマン－ラ ロシュ アーゲー |
非経口タンパク質溶液における可視粒子の形成を防止するためのキレート剤の使用
|
|
CA3184495A1
(en)
|
2020-06-08 |
2021-12-16 |
F. Hoffmann-La Roche Ag |
Anti-hbv antibodies and methods of use
|
|
CR20220637A
(es)
|
2020-06-19 |
2023-01-31 |
Hoffmann La Roche |
Anticuerpos que se unen a cd3 y cd19
|
|
BR112022025536A2
(pt)
|
2020-06-19 |
2023-01-17 |
Chugai Pharmaceutical Co Ltd |
Molécula de ligação ao antígeno de células anti-t para uso em combinação com o inibidor da angiogênese
|
|
IL296089A
(en)
|
2020-06-19 |
2022-11-01 |
Hoffmann La Roche |
Antibodies bind to cd3
|
|
AR122656A1
(es)
|
2020-06-19 |
2022-09-28 |
Hoffmann La Roche |
Anticuerpos que se unen a cd3 / folr1
|
|
WO2021255146A1
(en)
|
2020-06-19 |
2021-12-23 |
F. Hoffmann-La Roche Ag |
Antibodies binding to cd3 and cea
|
|
EP4168007A1
(en)
|
2020-06-23 |
2023-04-26 |
Novartis AG |
Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
|
EP4172192A1
(en)
|
2020-06-24 |
2023-05-03 |
Genentech, Inc. |
Apoptosis resistant cell lines
|
|
US20240279353A1
(en)
|
2020-07-06 |
2024-08-22 |
Kiromic BioPharma, Inc. |
Mesothelin isoform binding molecules and chimeric pd1 receptor molecules, cells containing the same and uses thereof
|
|
EP4178529A1
(en)
|
2020-07-07 |
2023-05-17 |
F. Hoffmann-La Roche AG |
Alternative surfactants as stabilizers for therapeutic protein formulations
|
|
EP4178530A1
(en)
|
2020-07-09 |
2023-05-17 |
F. Hoffmann-La Roche AG |
Concentrated compositions of proteins, their preparation and use thereof
|
|
CA3176556A1
(en)
|
2020-07-16 |
2022-01-20 |
Novartis Ag |
Anti-betacellulin antibodies, fragments thereof, and multi-specific binding molecules
|
|
CA3185122A1
(en)
|
2020-07-17 |
2022-01-20 |
Cecilia Pui Chi Chiu |
Anti-notch2 antibodies and methods of use
|
|
IL299860A
(en)
|
2020-07-21 |
2023-03-01 |
Genentech Inc |
Antibody-conjugated chemical factors for the discharge of BRM and their methods
|
|
WO2022026592A2
(en)
|
2020-07-28 |
2022-02-03 |
Celltas Bio, Inc. |
Antibody molecules to coronavirus and uses thereof
|
|
GB2597532A
(en)
|
2020-07-28 |
2022-02-02 |
Femtogenix Ltd |
Cytotoxic compounds
|
|
EP4188549A1
(en)
|
2020-08-03 |
2023-06-07 |
Novartis AG |
Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
JP2023539645A
(ja)
|
2020-08-26 |
2023-09-15 |
マレンゴ・セラピューティクス，インコーポレーテッド |
Ｎｋｐ３０に結合する抗体分子およびその使用
|
|
CA3190573A1
(en)
|
2020-08-26 |
2022-03-03 |
Andreas Loew |
Methods of detecting trbc1 or trbc2
|
|
AU2021331075A1
(en)
|
2020-08-26 |
2023-04-06 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
|
JP2023539201A
(ja)
|
2020-08-28 |
2023-09-13 |
ジェネンテック， インコーポレイテッド |
宿主細胞タンパク質のＣＲＩＳＰＲ／Ｃａｓ９マルチプレックスノックアウト
|
|
US20230321285A1
(en)
|
2020-08-31 |
2023-10-12 |
Advanced Accelerator Applications International Sa |
Method of treating psma-expressing cancers
|
|
WO2022043558A1
(en)
|
2020-08-31 |
2022-03-03 |
Advanced Accelerator Applications International Sa |
Method of treating psma-expressing cancers
|
|
CN116323663A
(zh)
|
2020-09-04 |
2023-06-23 |
豪夫迈·罗氏有限公司 |
与vegf-a和ang2结合的抗体及其使用方法
|
|
WO2022061214A1
(en)
|
2020-09-21 |
2022-03-24 |
Genentech, Inc. |
Purification of multispecific antibodies
|
|
KR20230068415A
(ko)
|
2020-09-24 |
2023-05-17 |
에프. 호프만-라 로슈 아게 |
유전자 녹아웃을 갖는 포유류 세포주
|
|
TW202446417A
(zh)
|
2020-10-05 |
2024-12-01 |
美商建南德克公司 |
用抗 fcrh5/抗 cd3 雙特異性抗體進行治療之給藥
|
|
WO2022082030A2
(en)
|
2020-10-15 |
2022-04-21 |
Gritstone Bio, Inc. |
Antigen-binding proteins and related methods of use
|
|
WO2022086957A1
(en)
|
2020-10-20 |
2022-04-28 |
Genentech, Inc. |
Peg-conjugated anti-mertk antibodies and methods of use
|
|
AU2021363536A1
(en)
|
2020-10-20 |
2023-02-23 |
F. Hoffmann-La Roche Ag |
Combination therapy of PD-1 axis binding antagonists and LRRK2 inhitibors
|
|
WO2022097065A2
(en)
|
2020-11-06 |
2022-05-12 |
Novartis Ag |
ANTIBODY Fc VARIANTS
|
|
KR20230107617A
(ko)
|
2020-11-13 |
2023-07-17 |
노파르티스 아게 |
키메라 항원 수용체(car)-발현 세포를 사용한 병용 요법
|
|
CR20230253A
(es)
|
2020-11-16 |
2023-07-26 |
Hoffmann La Roche |
Glucoformas de fab ricas en manosa
|
|
CA3202233A1
(en)
|
2020-11-18 |
2022-05-27 |
Kiromic BioPharma, Inc. |
Gamma-delta t cell manufacturing processes and chimeric pd1 receptor molecules
|
|
JP2023553399A
(ja)
|
2020-12-02 |
2023-12-21 |
アレクトル エルエルシー |
抗ソルチリン抗体の使用法
|
|
IL303633A
(en)
|
2020-12-15 |
2023-08-01 |
Merus Nv |
Cancer treatment with an antibody that binds LGR5 and EGFR
|
|
WO2022129120A1
(en)
|
2020-12-17 |
2022-06-23 |
F. Hoffmann-La Roche Ag |
Anti-hla-g antibodies and use thereof
|
|
CN117582496A
(zh)
|
2020-12-18 |
2024-02-23 |
美勒斯公司 |
抗体组合物
|
|
EP4740951A3
(en)
|
2020-12-22 |
2026-08-05 |
Foundation Medicine, Inc. |
Igh rearrangements and uses thereof
|
|
CN116670282A
(zh)
|
2020-12-22 |
2023-08-29 |
豪夫迈·罗氏有限公司 |
靶向xbp1的寡核苷酸
|
|
WO2022155503A1
(en)
|
2021-01-14 |
2022-07-21 |
Gritstone Bio, Inc. |
Multi-specific antibodies and methods of use
|
|
EP4284510A1
(en)
|
2021-01-29 |
2023-12-06 |
Novartis AG |
Dosage regimes for anti-cd73 and anti-entpd2 antibodies and uses thereof
|
|
AU2022218137A1
(en)
|
2021-02-03 |
2023-08-24 |
Mozart Therapeutics, Inc. |
Binding agents and methods of using the same
|
|
EP4288458A1
(en)
|
2021-02-03 |
2023-12-13 |
Genentech, Inc. |
Multispecific binding protein degrader platform and methods of use
|
|
EP4304732A1
(en)
|
2021-03-12 |
2024-01-17 |
Genentech, Inc. |
Anti-klk7 antibodies, anti-klk5 antibodies, multispecific anti-klk5/klk7 antibodies, and methods of use
|
|
EP4454652A3
(en)
|
2021-03-15 |
2025-05-21 |
F. Hoffmann-La Roche AG |
Compositions and methods for treating lupus nephritis
|
|
US20240174746A1
(en)
|
2021-03-18 |
2024-05-30 |
Alector Llc |
Anti-tmem106b antibodies and methods of use thereof
|
|
WO2022197877A1
(en)
|
2021-03-19 |
2022-09-22 |
Genentech, Inc. |
Methods and compositions for time delayed bio-orthogonal release of cytotoxic agents
|
|
EP4314063A1
(en)
|
2021-03-23 |
2024-02-07 |
Alector LLC |
Anti-tmem106b antibodies for treating and preventing coronavirus infections
|
|
WO2022201122A1
(en)
|
2021-03-26 |
2022-09-29 |
Janssen Biotech, Inc. |
Humanized antibodies against paired helical filament tau and uses thereof
|
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
|
|
CA3214757A1
(en)
|
2021-04-08 |
2022-10-13 |
Andreas Loew |
Multifuntional molecules binding to tcr and uses thereof
|
|
JP2024513474A
(ja)
|
2021-04-09 |
2024-03-25 |
エフ． ホフマン－ラ ロシュ アーゲー |
異種ポリペプチドを発現する細胞クローンを選択するための方法
|
|
WO2022217022A1
(en)
|
2021-04-10 |
2022-10-13 |
Profoundbio Us Co. |
Folr1 binding agents, conjugates thereof and methods of using the same
|
|
AR125344A1
(es)
|
2021-04-15 |
2023-07-05 |
Chugai Pharmaceutical Co Ltd |
Anticuerpo anti-c1s
|
|
JP2024514222A
(ja)
|
2021-04-19 |
2024-03-28 |
ジェネンテック， インコーポレイテッド |
改変された哺乳動物細胞
|
|
AU2022261268A1
(en)
|
2021-04-22 |
2023-11-16 |
Guangdong Fapon Biopharma Inc. |
Bispecific multifunctional fusion polypeptide
|
|
CA3216459A1
(en)
|
2021-04-23 |
2022-10-27 |
Profoundbio Us Co. |
Anti-cd70 antibodies, conjugates thereof and methods of using the same
|
|
CA3213632A1
(en)
|
2021-04-30 |
2022-11-03 |
F. Hoffmann-La Roche Ag |
Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
|
|
WO2022228706A1
(en)
|
2021-04-30 |
2022-11-03 |
F. Hoffmann-La Roche Ag |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibody
|
|
EP4337266A1
(en)
|
2021-05-12 |
2024-03-20 |
Genentech, Inc. |
Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
|
|
AR125874A1
(es)
|
2021-05-18 |
2023-08-23 |
Novartis Ag |
Terapias de combinación
|
|
CN117396599A
(zh)
|
2021-05-21 |
2024-01-12 |
基因泰克公司 |
用于生产目的重组产物的经修饰的细胞
|
|
CA3217029A1
(en)
|
2021-05-30 |
2022-12-08 |
Biolojic Design Ltd. |
Engineered dual binding antibodies and uses thereof
|
|
TW202313972A
(zh)
|
2021-06-03 |
2023-04-01 |
荷蘭商美勒斯公司 |
新ｎｒｇ１融合物、融合接合處及檢測彼等之方法
|
|
JP2024520261A
(ja)
|
2021-06-04 |
2024-05-24 |
中外製薬株式会社 |
抗ｄｄｒ２抗体およびその使用
|
|
IL308015A
(en)
|
2021-06-09 |
2023-12-01 |
Hoffmann La Roche |
Combination of a particular braf inhibitor (paradox breaker) and a pd-1 axis binding antagonist for use in the treatment of cancer
|
|
JP2024523034A
(ja)
|
2021-06-18 |
2024-06-25 |
エフ． ホフマン－ラ ロシュ アーゲー |
二重特異性抗ｃｃｌ２抗体
|
|
CN117616123B
(zh)
|
2021-06-25 |
2024-11-08 |
中外制药株式会社 |
抗ctla-4抗体
|
|
IL308633B2
(en)
|
2021-06-25 |
2025-12-01 |
Chugai Pharmaceutical Co Ltd |
Use of anti-ctla-4 antibody
|
|
WO2023287663A1
(en)
|
2021-07-13 |
2023-01-19 |
Genentech, Inc. |
Multi-variate model for predicting cytokine release syndrome
|
|
JP2024528631A
(ja)
|
2021-07-22 |
2024-07-30 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
ヘテロ二量体Ｆｃドメイン抗体
|
|
JP2024526880A
(ja)
|
2021-07-22 |
2024-07-19 |
ジェネンテック， インコーポレイテッド |
脳標的化組成物及びその使用方法
|
|
JP2024528217A
(ja)
|
2021-08-03 |
2024-07-26 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
二重特異性抗体および使用方法
|
|
CN117897409A
(zh)
|
2021-08-13 |
2024-04-16 |
基因泰克公司 |
抗类胰蛋白酶抗体的给药
|
|
WO2023028591A1
(en)
|
2021-08-27 |
2023-03-02 |
Genentech, Inc. |
Methods of treating tau pathologies
|
|
TW202325727A
(zh)
|
2021-08-30 |
2023-07-01 |
美商建南德克公司 |
抗聚泛素多特異性抗體
|
|
WO2023044483A2
(en)
|
2021-09-20 |
2023-03-23 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
|
TW202330594A
(zh)
|
2021-09-29 |
2023-08-01 |
美商莫德斯醫療公司 |
抗原結合多肽、抗原結合多肽複合物及其使用方法
|
|
CN120504741A
(zh)
|
2021-10-06 |
2025-08-19 |
美勒斯公司 |
使用至少结合egfr的抗体治疗免疫检查点抑制剂治疗的具高egfr表达的癌症
|
|
EP4413998A4
(en)
|
2021-10-08 |
2026-02-25 |
Chugai Pharmaceutical Co Ltd |
METHOD FOR PREPARING A PRE-FILLED SYRINGE FORMULATION
|
|
WO2023076876A1
(en)
|
2021-10-26 |
2023-05-04 |
Mozart Therapeutics, Inc. |
Modulation of immune responses to viral vectors
|
|
WO2023086807A1
(en)
|
2021-11-10 |
2023-05-19 |
Genentech, Inc. |
Anti-interleukin-33 antibodies and uses thereof
|
|
WO2023091887A1
(en)
|
2021-11-16 |
2023-05-25 |
Genentech, Inc. |
Methods and compositions for treating systemic lupus erythematosus (sle) with mosunetuzumab
|
|
WO2023092004A1
(en)
|
2021-11-17 |
2023-05-25 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of tau-related disorders
|
|
KR20240011866A
(ko)
|
2021-12-01 |
2024-01-26 |
추가이 세이야쿠 가부시키가이샤 |
항체 함유 제제의 조제 방법
|
|
AR127887A1
(es)
|
2021-12-10 |
2024-03-06 |
Hoffmann La Roche |
Anticuerpos que se unen a cd3 y plap
|
|
CN118401674A
(zh)
|
2021-12-21 |
2024-07-26 |
豪夫迈·罗氏有限公司 |
用于确定水解活性的方法
|
|
WO2023141445A1
(en)
|
2022-01-19 |
2023-07-27 |
Genentech, Inc. |
Anti-notch2 antibodies and conjugates and methods of use
|
|
AR128330A1
(es)
|
2022-01-26 |
2024-04-17 |
Genentech Inc |
Inductores químicos de degradación conjugados con anticuerpo y métodos de estos
|
|
AR128331A1
(es)
|
2022-01-26 |
2024-04-17 |
Genentech Inc |
Inductores químicos de degradación conjugados con anticuerpos y métodos de estos
|
|
TW202342548A
(zh)
|
2022-02-07 |
2023-11-01 |
美商威特拉公司 |
抗獨特型(anti-idiotype)抗體分子及其用途
|
|
EP4490185A1
(en)
|
2022-03-11 |
2025-01-15 |
JANSSEN Pharmaceutica NV |
Multispecific antibodies and uses thereof
|
|
TW202400636A
(zh)
|
2022-03-11 |
2024-01-01 |
比利時商健生藥品公司 |
多特異性抗體及其用途(一)
|
|
CA3254442A1
(en)
|
2022-03-11 |
2023-09-14 |
Janssen Pharmaceutica Nv |
MULTISPECIFIC ANTIBODIES AND THEIR USES
|
|
US20230414750A1
(en)
|
2022-03-23 |
2023-12-28 |
Hoffmann-La Roche Inc. |
Combination treatment of an anti-cd20/anti-cd3 bispecific antibody and chemotherapy
|
|
WO2023191816A1
(en)
|
2022-04-01 |
2023-10-05 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
|
TW202545564A
(zh)
|
2022-04-13 |
2025-12-01 |
美商建南德克公司 |
治療性蛋白質之醫藥組成物及使用方法
|
|
WO2023198727A1
(en)
|
2022-04-13 |
2023-10-19 |
F. Hoffmann-La Roche Ag |
Pharmaceutical compositions of anti-cd20/anti-cd3 bispecific antibodies and methods of use
|
|
EP4511388A1
(en)
|
2022-04-19 |
2025-02-26 |
F. Hoffmann-La Roche AG |
Improved production cells
|
|
KR20250005335A
(ko)
|
2022-04-26 |
2025-01-09 |
추가이 세이야쿠 가부시키가이샤 |
의약 제제 함유 필터 내장 시린지
|
|
PE20242350A1
(es)
|
2022-05-03 |
2024-12-16 |
Genentech Inc |
Anticuerpos anti-ly6e, inmunoconjugados y usos de estos
|
|
JP2025517650A
(ja)
|
2022-05-11 |
2025-06-10 |
ジェネンテック， インコーポレイテッド |
抗ＦｃＲＨ５／抗ＣＤ３二重特異性抗体による処置のための投与
|
|
WO2023220695A2
(en)
|
2022-05-13 |
2023-11-16 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
|
JP2025517572A
(ja)
|
2022-06-03 |
2025-06-05 |
エフ． ホフマン－ラ ロシュ アーゲー |
改良された産生細胞
|
|
CN119585308A
(zh)
|
2022-07-13 |
2025-03-07 |
基因泰克公司 |
针对用抗fcrh5/抗cd3双特异性抗体进行的治疗的给药
|
|
KR20250040020A
(ko)
|
2022-07-19 |
2025-03-21 |
제넨테크, 인크. |
항-fcrh5/항-cd3 이중특이성 항체로 치료하기 위한 투약법
|
|
CN119654349A
(zh)
|
2022-07-22 |
2025-03-18 |
基因泰克公司 |
抗steap1抗原结合分子及其用途
|
|
CA3263767A1
(en)
|
2022-08-03 |
2024-02-08 |
Voyager Therapeutics, Inc. |
COMPOSITIONS AND PROCESSES ALLOWING CROSSING THE BLOOD-BRAIN BARRIER
|
|
WO2024030956A2
(en)
|
2022-08-03 |
2024-02-08 |
Mozart Therapeutics, Inc. |
Cd39-specific binding agents and methods of using the same
|
|
TW202430211A
(zh)
|
2022-10-10 |
2024-08-01 |
瑞士商赫孚孟拉羅股份公司 |
Ｇｐｒｃ５ｄ ｔｃｂ及ｉｍｉｄ之組合療法
|
|
TW202423969A
(zh)
|
2022-10-10 |
2024-06-16 |
瑞士商赫孚孟拉羅股份公司 |
Ｇｐｒｃ５ｄ ｔｃｂ及蛋白酶體抑制劑之組合療法
|
|
TW202423970A
(zh)
|
2022-10-10 |
2024-06-16 |
瑞士商赫孚孟拉羅股份公司 |
Ｇｐｒｃ５ｄ ｔｃｂ及ｃｄ３８抗體之組合療法
|
|
JP2025535744A
(ja)
|
2022-10-12 |
2025-10-28 |
エフ． ホフマン－ラ ロシュ アーゲー |
細胞を分類するための方法
|
|
WO2024086796A1
(en)
|
2022-10-20 |
2024-04-25 |
Alector Llc |
Anti-ms4a4a antibodies with amyloid-beta therapies
|
|
JP2026500084A
(ja)
|
2022-10-25 |
2026-01-06 |
ジェネンテック， インコーポレイテッド |
多発性骨髄腫の治療方法および診断方法
|
|
WO2024094741A1
(en)
|
2022-11-03 |
2024-05-10 |
F. Hoffmann-La Roche Ag |
Combination therapy with anti-cd19/anti-cd28 bispecific antibody
|
|
IL320029A
(en)
|
2022-11-08 |
2025-06-01 |
Genentech Inc |
Compositions and methods for treating childhood idiopathic nephrotic syndrome
|
|
JP2025538565A
(ja)
|
2022-11-23 |
2025-11-28 |
エフ． ホフマン－ラ ロシュ アーゲー |
組換えタンパク質発現を増加させるための方法
|
|
EP4588936A4
(en)
|
2022-12-08 |
2026-08-12 |
Changchun Bcht Biotechnology Co |
ANTIBODIES THAT BIND SPECIFICALLY TO VRS
|
|
EP4634397A1
(en)
|
2022-12-12 |
2025-10-22 |
Genentech Inc. |
Optimizing polypeptide sialic acid content
|
|
JP2025541200A
(ja)
|
2022-12-15 |
2025-12-18 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
がん処置のための併用療法
|
|
WO2024136658A1
(en)
|
2022-12-23 |
2024-06-27 |
Merus N.V. |
Combination treatment of cancers using an antibody that binds at least egfr and an immune checkpoint inhibitor
|
|
IL321816A
(en)
|
2022-12-28 |
2025-08-01 |
Merus Nv |
Treatment of cancer with a combination of an antibody that binds egfr and cytotoxic drugs
|
|
EP4655322A1
(en)
|
2023-01-25 |
2025-12-03 |
F. Hoffmann-La Roche AG |
Antibodies binding to csf1r and cd3
|
|
WO2024168061A2
(en)
|
2023-02-07 |
2024-08-15 |
Ayan Therapeutics Inc. |
Antibody molecules binding to sars-cov-2
|
|
CN120826234A
(zh)
|
2023-03-06 |
2025-10-21 |
豪夫迈·罗氏有限公司 |
抗EGFRvIII/抗CD3抗体与肿瘤靶向性4-1BB激动剂的组合疗法
|
|
EP4676951A1
(en)
|
2023-03-10 |
2026-01-14 |
Genentech Inc. |
Fusions with proteases and uses thereof
|
|
KR20250167591A
(ko)
|
2023-03-31 |
2025-12-01 |
제넨테크, 인크. |
항-알파 v 베타 8 인테그린 항체 및 사용 방법
|
|
KR20260012304A
(ko)
|
2023-04-17 |
2026-01-26 |
피크 바이오, 인크. |
항체 및 항체-약물 접합체 및 사용 방법 및 합성 공정 및 중간체
|
|
WO2024233341A1
(en)
|
2023-05-05 |
2024-11-14 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
|
AU2024269754A1
(en)
|
2023-05-08 |
2025-10-23 |
F. Hoffmann-La Roche Ag |
Targeted interferon alpha fusion proteins and methods of use
|
|
AU2024268933A1
(en)
|
2023-05-10 |
2025-11-20 |
Chugai Seiyaku Kabushiki Kaisha |
Methods and compositions for treating cancer
|
|
EP4720124A1
(en)
|
2023-05-24 |
2026-04-08 |
Mozart Therapeutics, Inc. |
Cd8-specific binding proteins and methods of using the same
|
|
TW202504929A
(zh)
|
2023-06-22 |
2025-02-01 |
美商建南德克公司 |
用於癌症治療之方法及組成物
|
|
JP2026522631A
(ja)
|
2023-06-22 |
2026-07-08 |
ジェネンテック， インコーポレイテッド |
抗体及びその使用
|
|
PE20260581A1
(es)
|
2023-07-26 |
2026-03-11 |
Hoffmann La Roche |
Anticuerpos que se unen a cd3
|
|
AU2024323186A1
(en)
|
2023-08-09 |
2026-01-15 |
F. Hoffmann-La Roche Ag |
Mono and multispecific anti-trem2 antibodies, methods and uses thereof
|
|
AU2024320793A1
(en)
|
2023-08-09 |
2026-03-12 |
F. Hoffmann-La Roche Ag |
Mono and multispecific anti-trem2 antibodies, methods and uses thereof
|
|
EP4761818A1
(en)
|
2023-08-18 |
2026-06-24 |
F. Hoffmann-La Roche AG |
Protease activatable fc domain binding molecules
|
|
AR133909A1
(es)
|
2023-09-25 |
2025-11-12 |
Hoffmann La Roche |
ANTICUERPO QUE SE UNE A C3bBb
|
|
AR133955A1
(es)
|
2023-09-26 |
2025-11-19 |
Profoundbio Us Co |
Agentes de unión a ptk7, conjugados de éstos y métodos de uso de los mismos
|
|
WO2025106474A1
(en)
|
2023-11-14 |
2025-05-22 |
Genentech, Inc. |
Therapeutic and diagnostic methods for treating cancer with anti-fcrh5/anti-cd3 bispecific antibodies
|
|
WO2025106634A1
(en)
|
2023-11-17 |
2025-05-22 |
Genentech, Inc. |
Mcl-1 inhibitor compounds and use in antibody drug conjugates
|
|
AU2024388998A1
(en)
|
2023-11-27 |
2026-05-28 |
Genmab A/S |
Antibodies and methods for ptk7 detection
|
|
WO2025122634A1
(en)
|
2023-12-05 |
2025-06-12 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of tau-related disorders
|
|
CN122459340A
(zh)
|
2023-12-14 |
2026-07-24 |
豪夫迈·罗氏有限公司 |
与folr1结合的抗体及使用方法
|
|
WO2025137086A1
(en)
|
2023-12-20 |
2025-06-26 |
Genentech, Inc. |
Reducing alpha-gal
|
|
CN122422356A
(zh)
|
2023-12-20 |
2026-07-17 |
豪夫迈·罗氏有限公司 |
与ceacam5结合的抗体
|
|
AU2024402334A1
(en)
|
2023-12-22 |
2026-05-28 |
F. Hoffmann-La Roche Ag |
Activatable fusion proteins and methods of use
|
|
TW202547866A
(zh)
|
2024-01-10 |
2025-12-16 |
丹麥商珍美寶股份有限公司 |
Ｓｌｉｔｒｋ６結合劑、其共軛物及使用彼之方法
|
|
WO2025172924A1
(en)
|
2024-02-15 |
2025-08-21 |
Janssen Biotech, Inc. |
Anti-transferrin receptor compositions and methods thereof
|
|
WO2025181219A1
(en)
|
2024-02-29 |
2025-09-04 |
Genmab A/S |
Egfr and c-met bispecific binding agents, conjugates thereof and methods of using the same
|
|
WO2025181189A1
(en)
|
2024-03-01 |
2025-09-04 |
F. Hoffmann-La Roche Ag |
Antibodies binding to cd3
|
|
WO2025215060A1
(en)
|
2024-04-11 |
2025-10-16 |
F. Hoffmann-La Roche Ag |
Antibodies that specifically bind modified oligonucleotides
|
|
WO2025222129A2
(en)
|
2024-04-19 |
2025-10-23 |
Mozart Therapeutics, Inc. |
Engineered cytokines and targeted cytokine delivery
|
|
TW202604943A
(zh)
|
2024-04-24 |
2026-02-01 |
美商建南德克公司 |
治療狼瘡性腎炎之組成物及方法
|
|
WO2025240781A2
(en)
|
2024-05-15 |
2025-11-20 |
Werewolf Therapeutics, Inc. |
Modified antibodies and immunoglobulin formats
|
|
WO2025244529A1
(en)
|
2024-05-22 |
2025-11-27 |
Merus N.V. |
Dosing regimen of an egfr binding and/or complement activating antibody
|
|
TW202606758A
(zh)
|
2024-05-31 |
2026-02-16 |
美商維泰克斯製藥公司 |
抗cd74抗體組合物及方法
|
|
WO2025261943A1
(en)
|
2024-06-18 |
2025-12-26 |
F. Hoffmann-La Roche Ag |
Anti-cancer combinations comprising mosperafenib and folfox or folfiri
|
|
WO2026006162A2
(en)
|
2024-06-24 |
2026-01-02 |
Genentech, Inc. |
B vitamin modulation
|
|
WO2026011013A1
(en)
|
2024-07-02 |
2026-01-08 |
Epibiologics, Inc. |
Binding agents and uses thereof
|
|
WO2026030464A1
(en)
|
2024-07-30 |
2026-02-05 |
Genentech, Inc. |
Dosage regimen for reducing cytokine release syndrome (crs) with anti-fcrh5/anti-cd3 bispecific antibodies in multiple myeloma therapy
|
|
WO2026036047A1
(en)
|
2024-08-08 |
2026-02-12 |
Altus Enterprises, Inc. |
Antibody molecules to fixa and fx and uses thereof
|
|
WO2026037841A1
(en)
|
2024-08-12 |
2026-02-19 |
ONA Therapeutics S.L. |
Anti-fgfr4 molecules and uses thereof
|
|
WO2026042013A1
(en)
|
2024-08-19 |
2026-02-26 |
Institute Of Molecular And Clinical Ophthalmology Basel (Iob) |
Mitochondrial therapy
|
|
WO2026041568A1
(en)
|
2024-08-20 |
2026-02-26 |
F. Hoffmann-La Roche Ag |
Antibodies binding to cd3 and dotam
|
|
WO2026050572A2
(en)
|
2024-08-29 |
2026-03-05 |
Marengo Therapeutics, Inc. |
Multifunctional molecules binding to tcr and uses thereof
|
|
US20260167709A1
(en)
|
2024-09-11 |
2026-06-18 |
Novartis Ag |
Antibodies targeting il-31
|
|
WO2026072685A1
(en)
|
2024-09-25 |
2026-04-02 |
Genentech, Inc. |
Compositions and methods of treating lupus nephritis
|
|
WO2026102093A1
(en)
|
2024-11-07 |
2026-05-15 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of tau-related disorders
|
|
WO2026102349A1
(en)
|
2024-11-08 |
2026-05-15 |
Genentech, Inc. |
Anti-interleukin-23 receptor vhh antibodies and uses thereof
|
|
WO2026121966A2
(en)
|
2024-12-06 |
2026-06-11 |
Merus B.V. |
Treatment of previously treated subjects having colorectal cancer using an anti-egfr rechallenge treatment with a bispecific antibody that binds egfr and lgr5
|
|
WO2026130279A2
(en)
|
2024-12-16 |
2026-06-25 |
Merus B.V. |
Treatment of previously treated subjects having colorectal cancer using an anti-egfr rechallenge treatment with a bispecific antibody that binds egfr and cmet
|
|
WO2026131910A1
(en)
|
2024-12-19 |
2026-06-25 |
F. Hoffmann-La Roche Ag |
Treatment of inflammatory lung disease by combined inhibition of il-33 and il-6 with bispecific antibodies
|
|
WO2026132145A1
(en)
|
2024-12-20 |
2026-06-25 |
F. Hoffmann-La Roche Ag |
Antibodies binding to tn-muc-1
|
|
WO2026132383A2
(en)
|
2024-12-20 |
2026-06-25 |
F. Hoffmann-La Roche Ag |
ANTIBODIES BINDING TO Tn-MUC-1
|
|
WO2026151679A1
(en)
|
2025-01-07 |
2026-07-16 |
Compass Therapeutics, Llc. |
Multispecific binding constructs targeting pd-1 and vegf and uses thereof
|